var title_f4_35_4656="Calculator: Diagnosis of endocarditis - Duke criteria for definite endocarditis";
var content_f4_35_4656=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"IPSS_form\" name=\"IPSS_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Diagnosis of endocarditis - Duke criteria for definite endocarditis",
"       </span>",
"       <br/>",
"       <br/>",
"       This calculator is undergoing review. When the review has been completed, an updated calculator will be available here. We apologize for any inconvenience, and appreciate your patience.",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"    </center>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_35_4656=[""].join("\n");
var outline_f4_35_4656=null;
var title_f4_35_4657="Eptaplatin: International drug information";
var content_f4_35_4657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Eptaplatin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Sunpla (KR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3902768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Alkylating Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F3466485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small cell lung cancer; stomach, cervical, and colon cancer",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F3466487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: I.V.: Refer to individual protocols: 360 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (range: 320-400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ); schedule varies by protocol/indication",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3466488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vial: 50 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10489 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_35_4657=[""].join("\n");
var outline_f4_35_4657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302633\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3902768\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466485\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466487\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821165\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466488\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10489\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10489|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_35_4658="Exencephaly2";
var content_f4_35_4658=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Exencephaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound showing exencephaly (acrania) during the first trimester. The facial bones are present; however, no distinct cranial vault is seen above the level of the forehead and the brain is exposed. As the pregnancy progresses the brain tissue will slough off and the classic appearance of fetal anencephaly will be apparent by the second trimester.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_35_4658=[""].join("\n");
var outline_f4_35_4658=null;
var title_f4_35_4659="Ocular cicatricial pemphigoid stage 2";
var content_f4_35_4659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Stage 2 ocular cicatricial pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the foreshortening of the inferior fornix of the conjunctiva.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_35_4659=[""].join("\n");
var outline_f4_35_4659=null;
var title_f4_35_4660="Children and heart disease (atherosclerosis)";
var content_f4_35_4660=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Children and heart disease (atherosclerosis) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?4/35/4660/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4660/contributors\" id=\"au1165\">",
"       Sarah D de Ferranti, MD, MPH",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4660/contributors\" id=\"au1692\">",
"       Jane W Newburger, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?4/35/4660/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4660/contributors\" id=\"se5611\">",
"       David R Fulton, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?4/35/4660/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4660/contributors\" id=\"de7255\">",
"       Melanie S Kim, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?4/35/4660?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CHILDREN AND HEART DISEASE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Atherosclerosis is the medical term used to describe the build-up of fat and cholesterol-filled plaques inside the arteries of the body. Atherosclerosis increases the risk of cardiovascular disease, such as heart attack and stroke, when it affects arteries that supply blood to the heart and brain.",
"    </p>",
"    <p>",
"     It is unusual for children or teenagers to have a heart attack or stroke as a result of atherosclerosis. This is because vessel narrowing, caused by atherosclerosis, takes many years to develop. However, the process of atherosclerosis begins in childhood. For most children, atherosclerosis is mild and progresses slowly. In some children, atherosclerosis worsens rapidly, increasing the risk of heart disease, and less commonly, stroke in early adult life.",
"    </p>",
"    <p>",
"     It is often possible to identify which children are at risk for atherosclerosis and to begin making improvements in lifestyle (like eating a healthy diet and exercising). In addition, medications may be prescribed for children with the greatest likelihood of developing early atherosclerosis. In the sections that follow, we will discuss childhood risk factors for early atherosclerosis and cardiovascular disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      IS MY CHILD AT RISK FOR ATHEROSCLEROSIS?",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Risk factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certain factors increase a child's risk of developing early atherosclerosis, including the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Overweight &ndash; Children and teenagers who are overweight or obese have a higher risk of developing high blood pressure, diabetes, and high cholesterol and lipids. In adults, these factors increase the risk for early atherosclerotic disease. Children who are",
"       <span class=\"nowrap\">",
"        overweight/obese",
"       </span>",
"       are more likely to be",
"       <span class=\"nowrap\">",
"        overweight/obese",
"       </span>",
"       as adults. In addition, there is increasing evidence that childhood obesity makes it more likely to have other risk factors that are associated with heart disease in early adulthood, such as high blood pressure or diabetes mellitus. The definitions of obesity and overweight for children and teenagers are described below. (See",
"       <a class=\"local\" href=\"#H17\">",
"        'Obesity'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       High blood pressure &ndash; Children and adolescents with high blood pressure are more likely to have high blood pressure as adults. High blood pressure in adulthood increases the risk of cardiovascular disease. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?37/28/38337?source=see_link\">",
"        \"Patient information: High blood pressure in children (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Family history of cardiovascular disease &ndash; Children whose parents or grandparents had a heart attack or stroke at an early age have twice the risk of developing cardiovascular disease. A family history of early-age cardiovascular disease is defined as a parent or grandparent who had a heart attack, a stroke, or peripheral vascular disease (blockages in the large blood vessels of the arms or legs) before the age of 56 years for men or 66 years for women.",
"      </li>",
"      <li>",
"       Exposure to cigarette smoke &ndash; Smoking and exposure to smoking increases the risk of developing early cardiovascular disease.",
"       <span class=\"nowrap\">",
"        Children/teenagers",
"       </span>",
"       who smoke themselves are likely to continue smoking into adulthood, thus increasing their risk of early cardiovascular disease.",
"      </li>",
"      <li>",
"       Underlying medical problems &ndash; Certain underlying medical problems increase the risk of early cardiovascular disease. These include diabetes, chronic kidney disease, heart transplantation, Kawasaki disease with coronary aneurysms, and treatment for cancer during childhood. Children with these problems are treated especially vigorously with lifestyle changes and sometimes medications to lower their risk. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=see_link\">",
"        \"Diseases associated with atherosclerosis in childhood\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Is testing for risk factors recommended?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Screening for cholesterol problems is recommended once for children ages 9 to 11 years and again at ages 17 to 21 years. Additionally, children ages two years and older who have one or more of the following risks should be screened (",
"     <a class=\"graphic graphic_table graphicRef63578 \" href=\"UTD.htm?36/10/37035\">",
"      table 1",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Family history of high cholesterol or lipids, early cardiovascular disease, or diabetes. Family history is defined as a parent, sibling, or grandparent with a heart attack, a stroke, or peripheral vascular disease (blockages in the large blood vessels of the arms or legs) before 55 years of age for men and &le;65 years of age for women.",
"      </li>",
"      <li>",
"       Medical diseases associated with cardiovascular disease.",
"      </li>",
"      <li>",
"       <span class=\"nowrap\">",
"        Overweight/obesity,",
"       </span>",
"       high blood pressure, or high cholesterol or lipids (see below).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Screening tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;The following screening tests are recommended for children who have one or more of the above risk factors:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Fasting cholesterol and lipid blood testing (drawn before the first meal or drink of the day)",
"      </li>",
"      <li>",
"       OR non-fasting total cholesterol and HDL for children screened purely because of age (9 to 11 years and 17 to 21 years)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     All children, especially those with a risk factor for atherosclerosis, should have yearly measurement of:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Blood pressure",
"      </li>",
"      <li>",
"       Height and weight and calculation of body mass index (BMI), which is a way to measure for overweight or obesity (see",
"       <a class=\"local\" href=\"#H17\">",
"        'Obesity'",
"       </a>",
"       below)",
"      </li>",
"      <li>",
"       Review of lifestyle issues, such as tobacco smoke exposure, exercise, diet, and sleep",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      MANAGEMENT OF CHILDREN WITH INCREASED RISK OF ATHEROSCLEROSIS",
"     </span>",
"    </p>",
"    <p>",
"     The management of children with an increased risk of cardiovascular disease includes the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Lifestyle changes, including increased exercise, changes in diet, avoiding exposure to cigarette smoke, or weight loss",
"      </li>",
"      <li>",
"       If necessary, one or more medications to treat high cholesterol",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       high blood pressure",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Is treatment necessary?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatment of atherosclerosis risk factors may prevent or delay the development of cardiovascular disease later in life. The decision about when to start treatment depends upon:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The severity of risk for future heart disease",
"      </li>",
"      <li>",
"       The risk of side effects of the treatment",
"      </li>",
"      <li>",
"       The effectiveness of the treatment",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Making healthy lifestyle changes (diet, exercise, weight control, avoiding smoking) is effective and has few risks. The use of a medication(s) requires more careful consideration. For each child or teenager, the clinical provider will work to individualize a treatment plan that has the greatest potential benefits and fewest risks.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      HIGH CHOLESTEROL AND LIPIDS",
"     </span>",
"    </p>",
"    <p>",
"     Cholesterol and lipids are measured by testing the blood level of several components, including total cholesterol, LDL (bad cholesterol), HDL (good cholesterol), and triglycerides. The most accurate time to measure these levels is before the first meal or drink of the day, 8 to 12 hours after the last meal (called fasting).",
"    </p>",
"    <p>",
"     The following levels are considered abnormal and may indicate a need for treatment:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Total cholesterol &gt;200",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (5.18",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"      </li>",
"      <li>",
"       Low-density lipoprotein (LDL) cholesterol &gt;130",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (3.36",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"      </li>",
"      <li>",
"       High-density lipoprotein (HDL) cholesterol &lt;40",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"      </li>",
"      <li>",
"       Triglycerides (TG) &gt;130",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Initial treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;The initial treatment for high cholesterol includes a combination of changes in diet and increased activity. These treatments are usually recommended for at least 6 to 12 months before considering the use of medication.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;Parents of children with elevated low-density lipoprotein levels should offer their child a low-saturated fat, low-cholesterol diet. Increasing fruits and vegetables, whole grains, low-fat or nonfat dairy products, beans, fish, and lean proteins can help to meet this goal.",
"    </p>",
"    <p>",
"     Children with high triglycerides should eat a diet without excessive carbohydrates, particularly \"refined\" carbohydrates (white rice, pasta, bread, desserts), which raise blood sugar and are low in fiber.",
"    </p>",
"    <p>",
"     Meeting with a dietitian or nutritionist can help families to set realistic, individual goals and make long-lasting changes. In most cases, the entire family should change their diet together to maximize the child's chances of success. More than one visit with a nutritionist is often necessary.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Activity",
"     </span>",
"     &nbsp;&mdash;&nbsp;Increasing daily activity can help to decrease the risk of cardiovascular disease and improve cholesterol levels. Most expert groups recommend that children get 30 to 60 minutes of exercise four to six days per week.",
"    </p>",
"    <p>",
"     For children who are not already active, the increase in activity should be gradual. For example, the initial goal may be to ride a bicycle outside for 10 minutes 3 times per week. Other options include joining a gym or YMCA, riding an exercise bike, or running on a treadmill; activity should be tailored to the child's age and interests.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Dietary supplements",
"     </span>",
"     &nbsp;&mdash;&nbsp;Dietary supplements, such as fiber and omega-3 fatty acids, are sometimes recommended to decrease LDL cholesterol and triglyceride levels. However, the best source of fiber is from dietary sources, such as fruits, vegetables, and whole grains. The best source of omega-3 fatty acids is fish. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"      \"Patient information: High-fiber diet (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;If changes in diet and activity do not decrease cholesterol levels enough after 6 to 12 months, or if a child's cholesterol or triglyceride levels are very high, one or more medications may be recommended. Medications do not permanently cure the problem but work to lower the child's risk factors.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Statins",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most commonly used medication to treat high cholesterol belongs to a class of drugs called statins. Several statins are approved for use in children. These medications are usually taken in pill form, once per day. More detailed information about use of statins in children is available separately. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23320?source=see_link\">",
"      \"Overview of the management of the child at risk for atherosclerosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      HIGH BLOOD PRESSURE",
"     </span>",
"    </p>",
"    <p>",
"     In children, the normal range for blood pressure (BP) is determined by the child's gender, age, and height. The normal range is expressed as a percentile, similar to charts used to track children's height and weight.",
"    </p>",
"    <p>",
"     As an example, if a child's BP is at the 90th percentile, this means that 90 percent of children who are that age, gender, and height have a lower BP.",
"    </p>",
"    <p>",
"     A child's blood pressure percentile can be calculated here for boys (",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"      calculator 1",
"     </a>",
"     ) or here for girls (",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"      calculator 2",
"     </a>",
"     ). Hypertension is defined as BP &gt;95th percentile. Prehypertension is defined as BP &gt;90th to the 95th percentile",
"     <strong>",
"      or",
"     </strong>",
"     if BP exceeds",
"     <span class=\"nowrap\">",
"      120/80",
"     </span>",
"     mmHg.",
"    </p>",
"    <p>",
"     Blood pressure may change in response to an individual's emotions and environment. Hypertension (sustained high blood pressure) is not usually diagnosed until blood pressure is measured as high on three separate occasions when the child is calm and in a quiet environment. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/28/38337?source=see_link\">",
"      \"Patient information: High blood pressure in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      When is treatment needed?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lifestyle changes (diet and increased activity) are initially recommended for most children with hypertension or prehypertension. One or more medications may be recommended if lifestyle changes are not effective, if the blood pressure is very elevated, or if the child has an underlying medical problem that causes high blood pressure.",
"    </p>",
"    <p>",
"     Treatment of high blood pressure in children is discussed in detail in a separate topic. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/58/931?source=see_link\">",
"      \"Patient information: High blood pressure treatment in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      OBESITY",
"     </span>",
"    </p>",
"    <p>",
"     Body mass index (BMI) is a measure of weight in relation to height, and is currently the best way to determine whether a child (&gt;2 years of age) is overweight or obese.",
"    </p>",
"    <p>",
"     Because children grow in height as well as weight, a \"normal\" BMI depends upon the child's age and sex. A tool that calculates BMI for boys (",
"     <a class=\"calc calc_patient\" href=\"UTD.htm?42/49/43796?source=see_link\">",
"      calculator 3",
"     </a>",
"     ) and girls (",
"     <a class=\"calc calc_patient\" href=\"UTD.htm?12/19/12596?source=see_link\">",
"      calculator 4",
"     </a>",
"     ) is available here.",
"    </p>",
"    <p>",
"     Children whose BMI is &gt;85th percentile are considered to be overweight while children whose BMI is &gt;95th percentile are considered to be obese.",
"    </p>",
"    <p>",
"     Treatment is generally recommended for children whose BMI is &gt;95th percentile for age and gender. Treatment usually includes making changes in diet, behavior, and increasing physical activity.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      CIGARETTE SMOKING",
"     </span>",
"    </p>",
"    <p>",
"     All patients and family members who smoke are counseled to quit smoking. Smoking, as well as exposure to second-hand smoke, has many health risks. Approaches to quitting smoking are described separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      \"Patient information: Quitting smoking (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      OTHER MEDICAL CONDITIONS THAT INCREASE RISK",
"     </span>",
"    </p>",
"    <p>",
"     A number of medical conditions, such as diabetes, chronic kidney disease, and Kawasaki disease, increase a child's risk of developing cardiovascular disease. Careful management and monitoring of these conditions can reduce the child's risk. More information about these conditions is available separately. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=see_link\">",
"      \"Diseases associated with atherosclerosis in childhood\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our Web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413448713\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5509781\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/5/23635?source=see_link\">",
"      Patient information: Atherosclerosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5509789\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/28/38337?source=see_link\">",
"      Patient information: High blood pressure in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/58/931?source=see_link\">",
"      Patient information: High blood pressure treatment in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31943?source=see_link\">",
"      Cardiac abnormalities in children and adolescents with systemic lupus erythematosus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link\">",
"      Cardiovascular sequelae of Kawasaki disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34888?source=see_link\">",
"      Cerebrotendinous xanthomatosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34249?source=see_link\">",
"      Comorbidities and complications of type 2 diabetes mellitus in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=see_link\">",
"      Diseases associated with atherosclerosis in childhood",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=see_link\">",
"      Evaluation of hypertension in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link\">",
"      Risk factors and development of atherosclerosis in childhood",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=see_link\">",
"      Ischemic stroke in children and young adults: Etiology and clinical features",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43608?source=see_link\">",
"      Ischemic stroke in children: Evaluation, initial management, and prognosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23320?source=see_link\">",
"      Overview of the management of the child at risk for atherosclerosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.heart.org/HEARTORG/GettingHealthy/HealthierKids/Healthier-Kids_UCM_304156_SubHomePage.jsp\">",
"      www.heart.org/HEARTORG/GettingHealthy/HealthierKids/Healthier-Kids_UCM_304156_SubHomePage.jsp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?4/35/4660/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?4/35/4660?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4660/abstract/1\">",
"      American Academy of Pediatrics. Cardiovascular risk reduction in high-risk pediatric populations. Pediatrics 2007; 119:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4660/abstract/2\">",
"      McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007; 115:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4660/abstract/3\">",
"      Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006; 114:2710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4660/abstract/4\">",
"      Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998; 338:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4660/abstract/5\">",
"      McGill HC Jr, McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 2000; 20:1998.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f4_35_4660=[""].join("\n");
var outline_f4_35_4660=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CHILDREN AND HEART DISEASE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           IS MY CHILD AT RISK FOR ATHEROSCLEROSIS?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           MANAGEMENT OF CHILDREN WITH INCREASED RISK OF ATHEROSCLEROSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           HIGH CHOLESTEROL AND LIPIDS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           HIGH BLOOD PRESSURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           OBESITY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           CIGARETTE SMOKING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           OTHER MEDICAL CONDITIONS THAT INCREASE RISK",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?36/10/37035\" title=\"table 1\">",
"           High chol treat PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        CALCULATORS",
"       </h1>",
"       <div id=\"relatedCalculators\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"           Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"           Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"UTD.htm?42/49/43796?source=related_link\" title=\"calculator 3\">",
"           Calculator: Body mass index for boys (Patient information)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"UTD.htm?12/19/12596?source=related_link\" title=\"calculator 4\">",
"           Calculator: Body mass index for girls (Patient information)",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f4_35_4661="Epidemiology of gastric cancer";
var content_f4_35_4661=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of gastric cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/35/4661/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4661/contributors\">",
"     Annie On On Chan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4661/contributors\">",
"     Benjamin C Y Wong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/35/4661/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4661/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/35/4661/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4661/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/35/4661/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric cancer has been described as early as 3000 BC in hieroglyphic inscriptions and papyri manuscripts from ancient Egypt. The first major statistical analysis of cancer incidence and mortality (using data gathered in Verona, Italy from 1760 to 1839) showed that gastric cancer was the most common and lethal cancer. It has remained one of the most important malignant diseases with significant geographical, ethnic, and socioeconomic differences in distribution.",
"   </p>",
"   <p>",
"    This topic review will focus on the epidemiology of gastric cancer. Risk factors are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/618?source=see_link\">",
"     \"Risk factors for gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91192772\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric cancer is one of the most common cancers",
"    <a class=\"external\" href=\"file://globocan.iarc.fr/factsheet.asp\">",
"     worldwide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 21,600 patients are diagnosed annually in the United States, of whom 10,990 are expected to die [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/2\">",
"     2",
"    </a>",
"    ]. Global, country-specific incidence rates are available in the World Health Organization",
"    <a class=\"external\" href=\"file://globocan.iarc.fr/\">",
"     GLOBOCAN database",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Gastric cancer used to be the leading cause of cancer deaths in the world until the 1980s when it was overtaken by lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The worldwide incidence of gastric cancer has declined rapidly over the recent few decades [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Part of the decline may be due to the recognition of certain risk factors such as H. pylori and other dietary and environmental risks. However, the decline clearly began before the discovery of H. pylori. The decline first took place in countries with low gastric cancer incidence such as the United States (beginning in the 1930s), while the decline in countries with high incidence like Japan was slower. In the United Kingdom, there was a consistent decline in incidence of gastric cancer, with a reduction in RR from 1.14 in 1971 to 1975 to 0.84 in 1996 to 2000 in men, and 1.18 in 1971 to 1975 to 0.81 in 1996 to 2000 in women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/10\">",
"     10",
"    </a>",
"    ]. In China, the decline was less dramatic than other countries; despite an overall decrease in gastric cancer incidence, an increase has been observed in the oldest and the youngest group, and a less remarkable decline has been observed among women than in men [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/11\">",
"     11",
"    </a>",
"    ]. Of note is that the age of onset of developing gastric cancer in Chinese population is younger than that in the West. In the United States, risk factors for noncardia gastric cancer include male gender, non-white race, and older age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/12\">",
"     12",
"    </a>",
"    ]. Between 1977 and 2006, the incidence rate for noncardia gastric cancer in the United States declined among all race and age groups except for whites aged 29 to 39 years for whom it increased [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/13\">",
"     13",
"    </a>",
"    ]. The rise in incidence of noncardia gastric cancer among those at 25 to 39 years is noteworthy since this may signal the introduction of new environmental factors.",
"   </p>",
"   <p>",
"    An interesting hypothesis is that the popularization of refrigerators marks a pivotal point for the decline [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Refrigerators improved the storage of food, thereby reducing salt-based preservation of food and preventing bacterial and fungal contamination. Refrigeration also allowed for fresh food and vegetables to be more readily available, which may be a valuable source of antioxidants important for cancer prevention.",
"   </p>",
"   <p>",
"    Despite the decline, the absolute number of new cases per year is increasing, mainly due to aging in the world population. Furthermore, for unclear reasons, the trend toward declining incidence has been interrupted and replaced by an upward trend in young patients in recent years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/16\">",
"     16",
"    </a>",
"    ]. Thus, gastric cancer will continue to represent an important cause of cancer and cancer-related mortality for the foreseeable future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GEOGRAPHICAL VARIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of gastric cancer varies with different geographic regions. Rates are highest in Eastern Asia, Eastern Europe, and South America, while the lowest rates are in North America and parts of Africa (",
"    <a class=\"graphic graphic_figure graphicRef57792 \" href=\"UTD.htm?30/11/30898\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/1\">",
"     1",
"    </a>",
"    ]. Over 70 percent of gastric cancers occur in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/1\">",
"     1",
"    </a>",
"    ]. Gastric cancer is more common in men than in women, in both developed and developing countries (",
"    <a class=\"graphic graphic_figure graphicRef66076 graphicRef77893 \" href=\"UTD.htm?33/3/33841\">",
"     figure 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are also substantial differences in incidence among different ethnic groups within the same region (see below). A difference in incidence and mortality from north to south has been observed in several countries, with the northern areas having a higher mortality risk than those in the south. This gradient is particularly marked in the northern hemisphere [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/17-19\">",
"     17-19",
"    </a>",
"    ], whereas in the southern hemisphere, the mortality risk tends to be higher in the southern parts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Japan, there appears to be a",
"    <span class=\"nowrap\">",
"     north/south",
"    </span>",
"    divide, with gastric cancer mortality and incidence higher in the northeastern prefectures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/22\">",
"     22",
"    </a>",
"    ]. In England and Wales, there is a twofold difference in mortality and incidence rates across the country, with lower levels in the south and east and higher levels in the north and west, particularly noticeable in northwest Wales [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/23\">",
"     23",
"    </a>",
"    ]. In China, the incidence and mortality of gastric cancer varies from province to province (generally very high in the north, but relatively low in the south) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/19,24\">",
"     19,24",
"    </a>",
"    ]. It appears that higher geographic latitudes are associated with a higher gastric cancer risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MIGRATION STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migration, and in particular, international migration, can lead to a change in risk, as the immigrants, especially second and third generations, adopt the lifestyle and consequently the local disease patterns. The risk of gastric cancer changes slowly in populations moving from high to low risk communities. Incidence rates in Japanese living in Hawaii are 24.3 and 11.1 in males and females, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/25\">",
"     25",
"    </a>",
"    ]. Although these rates are about one-third of those found in Japan, they are nonetheless three times the rates in United States whites. Studies of Japanese migrants to the Unites States have confirmed that early exposure to environmental rather than genetic factors have a greater influence on mortality and incidence rates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In the subsequent generations born in the United States, the mortality rate declined towards the lower rate of United States whites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHANGE IN HISTOLOGY PATTERN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diffuse and intestinal types of gastric cancer as classified by Lauren [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/27\">",
"     27",
"    </a>",
"    ] describe two biological entities that are different with regard to epidemiology, etiology, pathogenesis, and behavior (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33194?source=see_link\">",
"     \"Pathology and molecular pathogenesis of gastric cancer\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intestinal gastric cancer is more common in males and older age groups. It is more prevalent in high-risk areas and is likely linked to environmental factors.",
"     </li>",
"     <li>",
"      The diffuse or infiltrative type, is equally frequent in both sexes, is more common in younger age groups, and has a worse prognosis than the intestinal type.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There has been a worldwide decline in the incidence of the intestinal type in recent few decades that parallels the overall decline in the incidence of gastric cancer. By contrast, the decline in the diffuse type has been more gradual. As a result, the diffuse type now accounts for approximately 30 percent of gastric carcinoma in some reported series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the decline in gastric cancer overall, there has been an explosive increase in incidence of cancer of the gastric cardia (",
"    <a class=\"graphic graphic_figure graphicRef79793 \" href=\"UTD.htm?4/45/4817\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The shift from distal to proximal stomach may in part be due to the decrease in the distal cancers. However, it has also been proposed that carcinoma at the cardia is a different entity from that of the rest of the gastric carcinoma.",
"   </p>",
"   <p>",
"    The proximal tumors share demographic and pathological features with Barrett's associated esophageal adenocarcinoma and are more likely to occur in men, which parallels the male predominance in the increasing incidence of carcinoma in the lower third of the esophagus. The proximal tumors also differ from distal tumors in that they are not associated with a severe form of gastritis characterized by atrophy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intestinal metaplasia. Furthermore, they tend to be more aggressive than those arising from distal sites. Environmental factors or chemical carcinogens (eg, cigarette and alcohol) may be more strongly associated with cardiac carcinomas compared with more distal carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=see_link\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647749897\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Global, country-specific mortality rates are available in the World Health Organization",
"    <a class=\"external\" href=\"file://globocan.iarc.fr/\">",
"     GLOBOCAN database",
"    </a>",
"    . There has been a steady decline in gastric cancer mortality. A study of gastric cancer mortality in Europe and other areas of the world between 1980 to 2005 demonstrated an annual percent change (APC) in gastric mortality rate around -3 to -4 percent for the major European countries. The APC rates were similar for the Republic of Korea (-4.3 percent), Japan (-3.5 percent), Australia (-3.7 percent), and the United States (-3.6 percent). In Latin America, the decline was less marked, but constant (-1.6 to -2.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4661/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastric cancer remains one of the most common forms of cancer worldwide. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The worldwide incidence of gastric cancer has declined rapidly over the recent few decades, the reasons for which are incompletely understood. However, the rate of decline has been variable in different regions.",
"     </li>",
"     <li>",
"      The incidence of gastric cancer varies with different geographic regions. The highest incidence rates are in Eastern Asia, the Andean regions of South America, and Eastern Europe while the lowest rates are in North America, Northern Europe, and most countries in Africa and South Eastern Asia. There is also substantial difference in the incidence among different ethnic groups within the same region. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Geographical variation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The histologic pattern of gastric cancer is also changing with a decline in the intestinal-type compared with the diffuse type. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Change in histology pattern'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There has been a steady decline in gastric cancer mortality worldwide, although the rate of decline differs by region. (See",
"      <a class=\"local\" href=\"#H647749897\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/3\">",
"      Parkin DM. Epidemiology of cancer: global patterns and trends. Toxicol Lett 1998; 102-103:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/4\">",
"      Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/5\">",
"      HAENSZEL W. Variation in incidence of and mortality from stomach cancer, with particular reference to the United States. J Natl Cancer Inst 1958; 21:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/6\">",
"      Mu&ntilde;oz N, Asvall J. Time trends of intestinal and diffuse types of gastric cancer in Norway. Int J Cancer 1971; 8:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/7\">",
"      Hirayama T. Epidemiology of cancer of the stomach with special reference to its recent decrease in Japan. Cancer Res 1975; 35:3460.",
"     </a>",
"    </li>",
"    <li>",
"     Cancer incidence in five continents. Waterhouse J, Muir C, Correa P, et al (Eds), Vol III, IARC Scientific Publication no.15, International Agency for Research on Cancer, Lyon 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/9\">",
"      Zhu AL, Sonnenberg A. Is gastric cancer again rising? J Clin Gastroenterol 2012; 46:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/10\">",
"      Fitzsimmons D, Osmond C, George S, Johnson CD. Trends in stomach and pancreatic cancer incidence and mortality in England and Wales, 1951-2000. Br J Surg 2007; 94:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/11\">",
"      Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/12\">",
"      Schlansky B, Sonnenberg A. Epidemiology of noncardia gastric adenocarcinoma in the United States. Am J Gastroenterol 2011; 106:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/13\">",
"      Anderson WF, Camargo MC, Fraumeni JF Jr, et al. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 2010; 303:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/14\">",
"      Coggon D, Barker DJ, Cole RB, Nelson M. Stomach cancer and food storage. J Natl Cancer Inst 1989; 81:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/15\">",
"      La Vecchia C, Negri E, D'Avanzo B, Franceschi S. Electric refrigerator use and gastric cancer risk. Br J Cancer 1990; 62:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/16\">",
"      Correa P. Gastric cancer: two epidemics? Dig Dis Sci 2011; 56:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/17\">",
"      WYNDER EL, KMET J, DUNGAL N, SEGI M. AN EPIDEMIOLOGICAL INVESTIGATION OF GASTRIC CANCER. Cancer 1963; 16:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/18\">",
"      Correa P, Haenszel W, Tannenbaum S. Epidemiology of gastric carcinoma: review and future prospects. Natl Cancer Inst Monogr 1982; 62:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/19\">",
"      Wong BC, Ching CK, Lam SK, et al. Differential north to south gastric cancer-duodenal ulcer gradient in China. China Ulcer Study Group. J Gastroenterol Hepatol 1998; 13:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/20\">",
"      Correa P, Cuello C, Duque E. Carcinoma and intestinal metaplasia of the stomach in Colombian migrants. J Natl Cancer Inst 1970; 44:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/21\">",
"      Cuello C, Correa P, Haenszel W, et al. Gastric cancer in Colombia. I. Cancer risk and suspect environmental agents. J Natl Cancer Inst 1976; 57:1015.",
"     </a>",
"    </li>",
"    <li>",
"     Kakizoe IW. Figures on cancer in Japan-1993. Foundation for Promotion of Cancer Research, Tokyo 1993.",
"    </li>",
"    <li>",
"     OPCS (Office of Population, Census and Surveys). 1994 Cancer statistics: Registrations in England and Wales (Series MB No.21). HMSO, London 1978.",
"    </li>",
"    <li>",
"     Chen JS, Campbell TC, Li JY, et al. Life-style and Mortality in China. A Study of the Characteristics of 65 Chinese Counties, Oxford University Press, Oxford 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/25\">",
"      Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968; 40:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/26\">",
"      Haenszel W, Kurihara M, Segi M, Lee RK. Stomach cancer among Japanese in Hawaii. J Natl Cancer Inst 1972; 49:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/27\">",
"      LAUREN P. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand 1965; 64:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/28\">",
"      Ikeda Y, Mori M, Kamakura T, et al. Improvements in diagnosis have changed the incidence of histological types in advanced gastric cancer. Br J Cancer 1995; 72:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/29\">",
"      Dupont JB Jr, Lee JR, Burton GR, Cohn I Jr. Adenocarcinoma of the stomach: review of 1,497 cases. Cancer 1978; 41:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/30\">",
"      Kampsch&ouml;er GH, Nakajima T, van de Velde CJ. Changing patterns in gastric adenocarcinoma. Br J Surg 1989; 76:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/31\">",
"      Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1990; 62:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/32\">",
"      Kalish RJ, Clancy PE, Orringer MB, Appelman HD. Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett's esophageal mucosa and in the gastric cardia. Gastroenterology 1984; 86:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4661/abstract/33\">",
"      Bertuccio P, Chatenoud L, Levi F, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer 2009; 125:666.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2616 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_35_4661=[""].join("\n");
var outline_f4_35_4661=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91192772\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GEOGRAPHICAL VARIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MIGRATION STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHANGE IN HISTOLOGY PATTERN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H647749897\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2616\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2616|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/11/30898\" title=\"figure 1\">",
"      Global incidence of gastric cancer in men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/20/14671\" title=\"figure 2A\">",
"      Cancer incidence in males in more and less developed countries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/48/34574\" title=\"figure 2B\">",
"      Cancer incidence in females in more and less developed countries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/45/4817\" title=\"figure 3\">",
"      Parts of the stomach",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33194?source=related_link\">",
"      Pathology and molecular pathogenesis of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/618?source=related_link\">",
"      Risk factors for gastric cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_35_4662="Echocardiography essentials: Physics and instrumentation";
var content_f4_35_4662=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Echocardiography essentials: Physics and instrumentation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/35/4662/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4662/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/35/4662/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4662/contributors\">",
"     Nelson B Schiller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/35/4662/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4662/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/35/4662/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is the primary noninvasive imaging modality for quantitative and qualitative evaluation of cardiac anatomy, physiology, and function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4662/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Two-dimensional (2D) echocardiography provides tomographic or \"thin-slice\" imaging. Comprehensive echocardiographic examination typically involves imaging the heart from multiple \"viewing\" orientations as well as with multiple imaging techniques (ie, 2D, Doppler). An understanding of the fundamental principles of cardiac ultrasound is necessary for the proper acquisition and interpretation of echocardiographic data.",
"   </p>",
"   <p>",
"    The basic physics principles that apply to echocardiography and its instrumentation are reviewed here. The normal anatomic views and protocols for echocardiography, as well as its clinical uses, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14167?source=see_link\">",
"     \"Transthoracic echocardiography: Normal cardiac anatomy and tomographic views\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ULTRASOUND WAVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sound waves are mechanical vibrations that can be described in terms of frequency or Hertz (Hz), ie, the number of repetitions or cycles per second. Other characteristics include wavelength, the distance between excitations, measured in mm; and the amplitude of excitation, measured in decibels (dB). A 6 dB change results in a doubling (or halving) of the signal amplitude.",
"   </p>",
"   <p>",
"    Medical ultrasound imaging typically uses sound waves at frequencies of 1,000,000 to 20,000,000 Hz (1.0 to 20 MHz). In contrast, the human auditory spectrum comprises frequencies between 20 and 20,000 Hz.",
"   </p>",
"   <p>",
"    Frequency and wavelength are mathematically related to the velocity of the ultrasound beam within the tissue (approximately 1,540,000",
"    <span class=\"nowrap\">",
"     mm/sec",
"    </span>",
"    for human tissue) as indicated by the following equations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Velocity of blood = Wavelength (mm) x frequency (Hz)",
"     </li>",
"     <li>",
"      Wavelength (mm) = 1,540,000",
"      <span class=\"nowrap\">",
"       mm/sec",
"      </span>",
"      &divide; frequency (Hz)",
"     </li>",
"     <li>",
"      Wavelength (mm) = 1.54 &divide; frequency (MHz)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The resolution of a recording, ie, the ability to distinguish two objects that are spatially close together, varies directly with the frequency and inversely with the wavelength. High frequency, short wavelength ultrasound can separate objects that are less than 1 mm apart. Echocardiographic image resolution is generally 1 or 2 wavelengths. Thus, imaging with a 2.5 MHz transducer would result in a resolution of approximately 1 mm.",
"   </p>",
"   <p>",
"    Imaging with higher frequency (and lower wavelength) transducers permits enhanced spatial resolution. However, because of attenuation, the depth of tissue penetration or the ability to transmit sufficient ultrasonic energy into the chest is directly related to wavelength and therefore inversely related to transducer frequency. As a result, the trade-off for use of higher frequency transducers is reduced tissue penetration.",
"   </p>",
"   <p>",
"    The trade-off between tissue resolution and penetration guides the choice of transducer frequency for clinical imaging. As an example, higher frequency transducers can be used in echocardiography for imaging of structures close to the transducer or the chest wall, such as the apex of the left ventricle with transthoracic imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INTERACTION OF ULTRASOUND WAVES WITH TISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an ultrasonic beam travels through a homogeneous medium, its path is a straight line. However, when the medium is not homogeneous or when the beam travels through a medium with two or more interfaces, its path is altered. The relationship between ultrasound waves and tissues can be described in terms of reflection, scattering, refraction, and attenuation. The last three factors all act to decrease the magnitude of the ultrasound wave.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reflection",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an ultrasound beam \"hits\" a tissue",
"    <span class=\"nowrap\">",
"     boundary/interface,",
"    </span>",
"    a certain amount of the ultrasound is reflected back to the transducer, like a mirror. The magnitude of the reflected wave is dependent on the acoustic impedance of the tissue:",
"   </p>",
"   <p>",
"    &nbsp;Acoustic impedance = tissue density x propagation velocity",
"   </p>",
"   <p>",
"    Tissues with increased density reflect a greater proportion of the ultrasound beam. The magnitude of the reflected beam which is received by the transducer is dependent upon the angle between the ultrasound beam and tissue interface. Since the angle of incidence equals the angle of reflection, the \"optimal\" return of the reflected ultrasound occurs at a 90&ordm; (perpendicular) orientation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Scattering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small structures, eg, less than 1 wavelength in lateral dimension, result in scattering of the ultrasound signal. Unlike a reflected beam, scattering results in the ultrasound beam being radiated in all directions, with minimal signal returning to the transducer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Refraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound waves can all be refracted, or deflected from their orientation, as they pass into a medium of different acoustic impedance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Attenuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ultrasound signal strength is progressively reduced due to absorption of the ultrasound energy by conversion to heat, a process called attenuation. Attenuation is frequency and, from the above formation, wavelength dependent. The depth of penetration is limited to approximately 200 wavelengths, corresponding to a depth of 30 cm for a 1 MHz transducer, 12 cm for 2.5 MHz transducer, and 6 cm for a 5 MHz transducer.",
"   </p>",
"   <p>",
"    Attenuation is also dependent upon acoustic impedance and any mismatch in impedance between adjacent structures. Air has a very high acoustic impedance, resulting in significant signal attenuation when imaging through lung tissue, especially emphysematous lung, or pathologic conditions such as pneumomediastinum or subcutaneous emphysema. In contrast, filling of the pleural space with fluid, generally enhances ultrasound imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ULTRASOUND TRANSDUCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound transducers use piezoelectric crystals to both generate and receive ultrasound waves. These crystals (quartz or titanate ceramic) alternately compress and expand the alternating electric current that is applied, thereby generating the ultrasound wave. Following a brief period of transmission, typically 1 to 6 &micro;sec, the same crystal also acts as a receiver. When a reflected ultrasound wave impacts the piezoelectric crystal, an electric current is generated.",
"   </p>",
"   <p>",
"    Image formation, which is related to the distance of a structure from the transducer, is based upon the time interval between ultrasound transmission and arrival of the reflected signal. The amplitude is proportional to the incident angle and acoustic impedance, and timing is proportional to the distance from the transducer.",
"   </p>",
"   <p>",
"    The simplest type of ultrasound transducer has a single piezoelectric crystal and is often used for M-mode recordings. Generation of a 2D image requires mechanical or electronic \"sweeping\" of the ultrasound beam across the plane of interest or sector. Initially, mechanical transducers physically moved a crystal. Today, phased-array transducers consist of a series of ultrasound crystals arranged so that they can be \"electronically\" steered, with no moving parts. The phased-array transducers are the most common type currently used for clinical echocardiography (",
"    <a class=\"graphic graphic_figure graphicRef52459 \" href=\"UTD.htm?6/55/7028\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In contrast to echocardiographic imaging, continuous-wave Doppler examinations utilize a pair of dedicated crystals: one for continuous transmission; and one for continuous receiving. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15365?source=see_link\">",
"     \"Principles of Doppler echocardiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RESOLUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Image resolution with 2D echocardiography can be considered in terms of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      \"Axial\" resolution along the length of the ultrasound beam",
"     </li>",
"     <li>",
"      \"Lateral\" resolution",
"     </li>",
"     <li>",
"      \"Elevational\" resolution which is the thickness of the tomographic \"slice\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Axial resolution is a function of the transducer frequency, bandwidth, and pulse length. Since the smallest resolvable distance between two specular reflections is 1 wavelength, higher-frequency transducers result in enhanced axial resolution. A wider bandwidth also improves resolution by allowing for a shorter pulse.",
"   </p>",
"   <p>",
"    Lateral resolution varies with transducer frequency, beam width, bandwidth, aperture (width) of the transducer, and side lobes. At greater depths, beam width diverges so that a point target results in a reflected signal as wide as the beam width. Beam width artifacts appear as a bright linear structure.",
"   </p>",
"   <p>",
"    The 2D tomographic image includes reflected and backscattered signals from the entire thickness. The thickness of the 2D image is variable over the image plane and is dependent upon the transducer design and focusing. Most clinical images have a \"thickness\" of 3 to 10 mm, depending on depth. Strong reflectors near the image plane may appear \"in\" the image plane due to elevational beam width.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Second harmonic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ultrasound wave traveling through tissue becomes distorted, which generates additional sound frequencies that are harmonics of the original or fundamental frequency. The sound wave becomes more distorted and produces more harmonics the further it travels through tissue. The technique of second harmonic imaging uses broadband transducers that receive double the transmitted frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4662/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. As a result, only the additional generated harmonics are received and the fundamental signal is filtered out; this acts as a form of depth compensation, effectively boosting the signal from deeper structures.",
"   </p>",
"   <p>",
"    Second harmonic imaging was initially developed to intensify the ultrasound signal during contrast echocardiography, since microbubble contrast agents emit harmonic frequencies when hit by ultrasound energy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4662/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23318?source=see_link\">",
"     \"Contrast echocardiography: Contrast agents, safety, and imaging technique\"",
"    </a>",
"    .) It can also help improve visualization of cardiac structures in echocardiography without the use of contrast. When compared to conventional imaging, it reduces variations in ultrasound intensity along endocardial and myocardial surfaces, enhancing these structures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4662/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This method is of particular benefit for patients in whom optimal echocardiographic images are technically difficult to obtain (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70900 \" href=\"UTD.htm?18/58/19363\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4662/abstract/5\">",
"     5",
"    </a>",
"    ]. As an example, one study found that second harmonic imaging enhances endocardial visibility and definition during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4662/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     IMAGING MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various echocardiographic modalities are in clinical use and each plays an important role in the evaluation of the heart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     M-mode",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motion or \"M\"-mode echocardiography is among the earliest forms of cardiac ultrasound. With this technique, a single crystal rapidly alternates between transmission and receiver modes with rapid updating (&gt;1000 Hz); as a result, rapidly moving structures (eg, valve leaflets) can be monitored for their characteristic motion. M-mode data can be recorded on paper or displayed on the video monitor at sweep speeds of 50 to 100",
"    <span class=\"nowrap\">",
"     mm/sec.",
"    </span>",
"    Although originally performed using dedicated crystals, alignment of the M-mode beam is now typically performed with 2D imaging guidance (",
"    <a class=\"graphic graphic_figure graphicRef61898 \" href=\"UTD.htm?30/0/30725\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The very high temporal resolution afforded by M-mode imaging permits the identification of subtle abnormalities such as fluttering of the anterior mitral leaflet due to aortic regurgitation or movement of vegetation. In addition, dimensional measurements or changes, such as chamber size and endocardial thickening, can be readily appreciated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Two-dimensional (2D) imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2D image is generated from data obtained mechanically (mechanical transducer) or electronically (phased-array transducer) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75034 graphicRef77446 graphicRef56587 graphicRef68826 \" href=\"UTD.htm?11/25/11673\">",
"     image 2A-D",
"    </a>",
"    ). Since each scan line of data requires a finite period of time for transmission and reception, the time required to complete each 2D image is directly related to the number of scan lines. Thus, there is a trade-off between scan line density and image frame rate. For cardiac applications, a high frame rate (at least 25",
"    <span class=\"nowrap\">",
"     frames/second;",
"    </span>",
"    40 msec frame rate) is desirable for most situations. The signal received undergoes a complex manipulation to form the final image displayed on the monitor including signal amplification, time-gain compensation, filtering, compression and rectification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Miniaturized echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiographic equipment has become smaller and more portable, with systems the size of a large smart phone or laptop computer are now available for point-of-care evaluation. Referred to as miniaturized, hand-held, or hand-carried echocardiography, these systems have been evaluated in a variety of situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients referred for a transthoracic echocardiogram, there was good correlation between hand-held and standard echocardiographic systems for left ventricular (LV) measurements, endocardial border visibility, regional wall motion assessment, and LV ejection fraction (LVEF) calculation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4662/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 175 patients with heart failure or heart failure symptoms seen by general practitioners, those with an abnormal echocardiogram (LVEF less than 50 percent, dilated LV or left atrium, LV hypertrophy, or any valve pathology) had a significantly higher rate of death or cardiovascular hospitalization over four years of follow-up (hazard ratio 5.55 compared to those with a normal echocardiogram, 95% CI 2.04 to 14.28) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4662/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As an addition to the physical examination in patients referred for outpatient cardiology consultation, hand-held echocardiography has been shown to substantially improve the detection of important cardiovascular pathology compared with physical examination alone [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4662/abstract/9\">",
"       9",
"      </a>",
"      ]. Another study of an abbreviated (average time three minutes) echocardiogram using a miniaturized system during outpatient cardiology consultation reported that the findings from echocardiography altered the decision regarding referral for a full echocardiogram in 45 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4662/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When used as part of a pre-participation screening program for college athletes, portable echocardiography yielded technically adequate images in 92 percent of those screened [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4662/abstract/11\">",
"       11",
"      </a>",
"      ]. Over the three-year period that the study was performed, the time required to complete the echocardiographic evaluation decreased significantly by over 35 percent (17.4 minutes in year one, 11 minutes in year three).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While miniaturized echocardiography does appear promising, with multiple potential applications, long-term data on the effectiveness of this technique in larger scale practice have not yet been reported, and as such, it is premature to advocate for the use of hand-held echocardiography as part of a routine clinical cardiology evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     BIOEFFECTS AND SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are",
"    <strong>",
"     no known adverse effects",
"    </strong>",
"    from diagnostic ultrasound at clinical imaging frequencies. Ultrasound does have significant bioeffects depending upon the intensity of the exposure. These include thermal effects, which predominate, and cavitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Thermal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;As an ultrasound beam passes through tissue, heat is produced due to the absorption of the mechanical energy generated by the sound wave. The rate of temperature increase is related to the absorption coefficient of the tissue for a given frequency, the density of the tissue, specific heat of the tissue, and the intensity of the ultrasound exposure.",
"   </p>",
"   <p>",
"    Increases in temperature due to ultrasound are offset by blood flow through the tissue and heat diffusion. More dense tissues, such as bone, heat more rapidly than less dense tissue, such as fat. The rise in temperature for soft tissue has been estimated to be as much as",
"    <span class=\"nowrap\">",
"     0.6&ordm;C/minute",
"    </span>",
"    of continuous ultrasound exposure. Since ultrasound exposure and transmission is intermittent, exposure time is far less than study time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cavitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cavitation is the creation or vibration of small gas-filled bodies by the ultrasound beam; it is more common using higher intensity exposures. Microbubbles resonate, expand, and contract depending upon their dimension in relation to the sound wave. Microbubbles can also be created by ultrasound due to expansion of small cavitation nuclei.",
"   </p>",
"   <p>",
"    The intensity of ultrasound can be expressed as the power per area during a unit time:",
"   </p>",
"   <p>",
"    &nbsp;Intensity =",
"    <span class=\"nowrap\">",
"     joules/time",
"    </span>",
"    x",
"    <span class=\"nowrap\">",
"     time/area",
"    </span>",
"    =",
"    <span class=\"nowrap\">",
"     joules/area",
"    </span>",
"    <span class=\"nowrap\">",
"     (watt/cm2)",
"    </span>",
"   </p>",
"   <p>",
"    The American Institute of Ultrasound in Medicine has recommended limits for ultrasound exposure. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &le;1&ordm;C elevation of tissue temperature",
"     </li>",
"     <li>",
"      &le;100",
"      <span class=\"nowrap\">",
"       mW/cm2",
"      </span>",
"      with unfocused and &le;1",
"      <span class=\"nowrap\">",
"       W/cm2",
"      </span>",
"      with focused ultrasound beams",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A major limitation of measuring the intensity of ultrasound exposure is that transmission is intermittent and the ultrasound beam does not penetrate the same area for prolonged periods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5894931\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the fundamental principles of cardiac ultrasound is necessary for the proper acquisition and interpretation of echocardiographic data.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sound wave characteristics include frequency, wavelength, and amplitude. The resolution of a recording (the ability to distinguish two objects that are spatially close together) varies directly with the frequency and inversely with the wavelength. Imaging with higher frequency (and lower wavelength) transducers permits enhanced spatial resolution. However, because of attenuation, the trade-off for use of higher frequency transducers is reduced tissue penetration. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ultrasound waves'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When an ultrasonic beam travels through a homogeneous medium, its path is a straight line. However, when the medium is not homogeneous or when the beam travels through a medium with two or more interfaces, its path is altered. The relationship between ultrasound waves and tissues can be described in terms of reflection, scattering, refraction, and attenuation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Interaction of ultrasound waves with tissues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound transducers use piezoelectric crystals to both generate and receive ultrasound waves. These crystals (quartz or titanate ceramic) alternately compress and expand the alternating electric current that is applied, thereby generating the ultrasound wave. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Ultrasound transducers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Image quality with 2D echocardiography is affected by axial resolution, lateral resolution, and elevational resolution. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Resolution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are",
"      <strong>",
"       no known adverse effects",
"      </strong>",
"      from diagnostic ultrasound at clinical imaging frequencies. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Bioeffects and safety'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4662/abstract/1\">",
"      Pearlman JD, Triulzi MO, King ME, et al. Limits of normal left ventricular dimensions in growth and development: analysis of dimensions and variance in the two-dimensional echocardiograms of 268 normal healthy subjects. J Am Coll Cardiol 1988; 12:1432.",
"     </a>",
"    </li>",
"    <li>",
"     Otto CM. Textbook of Clinical Echocardiography, 4th edition, Saunders Elsevier, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4662/abstract/3\">",
"      Caidahl K, Kazzam E, Lidberg J, et al. New concept in echocardiography: harmonic imaging of tissue without use of contrast agent. Lancet 1998; 352:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4662/abstract/4\">",
"      Spencer KT, Bednarz J, Rafter PG, et al. Use of harmonic imaging without echocardiographic contrast to improve two-dimensional image quality. Am J Cardiol 1998; 82:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4662/abstract/5\">",
"      Main ML, Asher CR, Rubin DN, et al. Comparison of tissue harmonic imaging with contrast (sonicated albumin echocardiography and Doppler myocardial imaging for enhancing endocardial border resolution. Am J Cardiol 1999; 83:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4662/abstract/6\">",
"      Franke A, Hoffmann R, K&uuml;hl HP, et al. Non-contrast second harmonic imaging improves interobserver agreement and accuracy of dobutamine stress echocardiography in patients with impaired image quality. Heart 2000; 83:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4662/abstract/7\">",
"      Prinz C, Voigt JU. Diagnostic accuracy of a hand-held ultrasound scanner in routine patients referred for echocardiography. J Am Soc Echocardiogr 2011; 24:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4662/abstract/8\">",
"      Lipczyska M, Szymaski P, Klisiewicz A, Hoffman P. Hand-carried echocardiography in heart failure and heart failure risk population: a community based prospective study. J Am Soc Echocardiogr 2011; 24:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4662/abstract/9\">",
"      Spencer KT, Anderson AS, Bhargava A, et al. Physician-performed point-of-care echocardiography using a laptop platform compared with physical examination in the cardiovascular patient. J Am Coll Cardiol 2001; 37:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4662/abstract/10\">",
"      Cardim N, Fernandez Golfin C, Ferreira D, et al. Usefulness of a new miniaturized echocardiographic system in outpatient cardiology consultations as an extension of physical examination. J Am Soc Echocardiogr 2011; 24:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4662/abstract/11\">",
"      Weiner RB, Wang F, Hutter AM Jr, et al. The feasibility, diagnostic yield, and learning curve of portable echocardiography for out-of-hospital cardiovascular disease screening. J Am Soc Echocardiogr 2012; 25:568.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5316 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_35_4662=[""].join("\n");
var outline_f4_35_4662=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5894931\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ULTRASOUND WAVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INTERACTION OF ULTRASOUND WAVES WITH TISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reflection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Scattering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Refraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Attenuation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ULTRASOUND TRANSDUCERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RESOLUTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Second harmonic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IMAGING MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      M-mode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Two-dimensional (2D) imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Miniaturized echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      BIOEFFECTS AND SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Thermal effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cavitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5894931\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5316\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5316|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/58/19363\" title=\"diagnostic image 1\">",
"      Harmonic imaging echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/7/19568\" title=\"diagnostic image 2A\">",
"      Apical 4 chamber view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/7/20592\" title=\"diagnostic image 2B\">",
"      2D TTE parasternal long axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/48/11008\" title=\"diagnostic image 2C\">",
"      2D TTE RV inflow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/30/10735\" title=\"diagnostic image 2D\">",
"      Short axis LV mitral valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5316|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/55/7028\" title=\"figure 1\">",
"      Echocardiogram instrumentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/0/30725\" title=\"figure 2\">",
"      M mode echo parasternal long axis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23318?source=related_link\">",
"      Contrast echocardiography: Contrast agents, safety, and imaging technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15365?source=related_link\">",
"      Principles of Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14167?source=related_link\">",
"      Transthoracic echocardiography: Normal cardiac anatomy and tomographic views",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_35_4663="Monilethrix";
var content_f4_35_4663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Monilethrix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Short brittle hair is present in this patient with monilethrix.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_35_4663=[""].join("\n");
var outline_f4_35_4663=null;
var title_f4_35_4664="Chloramphenicol: Pediatric drug information";
var content_f4_35_4664=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chloramphenicol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"    see \"Chloramphenicol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/3/20532?source=see_link\">",
"    see \"Chloramphenicol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Chloromycetin&reg;;",
"     </li>",
"     <li>",
"      Chloromycetin&reg; Succinate;",
"     </li>",
"     <li>",
"      Diochloram&reg;;",
"     </li>",
"     <li>",
"      Pentamycetin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Initial loading dose: 20 mg/kg (the first maintenance dose should be given 12 hours after the loading dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA &le;7 days and &le;2000 g: 25 mg/kg/day once every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA &gt;7 days and &le;2000 g: 25 mg/kg/day once every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA &gt;7 days and &gt;2000 g: 50 mg/kg/day divided every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"      see \"Chloramphenicol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Meningitis: Maintenance dose: 75-100 mg/kg/day divided every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Other infections: 50-75 mg/kg/day divided every 6 hours; maximum daily dose: 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 50-100 mg/kg/day in divided doses every 6 hours; maximum daily dose: 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal and/or hepatic impairment:",
"     </b>",
"     Dose reduction should be based upon serum chloramphenicol concentrations",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g [contains sodium [~52 mg (2.25 mEq)/g]]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Do not administer I.M. Can administer I.V. push over 5 minutes at a maximum concentration of 100 mg/mL, or I.V. intermittent infusion over 15-30 minutes at a final concentration for administration &le;20 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F149489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, fat emulsion 10%, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, cyclophosphamide, cyclosporine, enalaprilat, esmolol, foscarnet, hydromorphone, labetalol, magnesium sulfate, meperidine, morphine, nicardipine, tacrolimus.",
"     <b>",
"      Incompatible",
"     </b>",
"     Fluconazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Ampicillin, cloxacillin, heparin, iohexol, iopamidol, iothalamate meglumine, ioxaglate meglumine and ioxaglate sodium, penicillin G sodium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Glycopyrrolate, metoclopramide.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstituted parenteral solution (100 mg/mL) is stable for 30 days at room temperature; frozen solutions remain stable for 6 months",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of serious infections due to organisms resistant to other less toxic antibiotics or when its penetrability into the site of infection is clinically superior to other antibiotics to which the organism is sensitive; useful in infections caused by",
"     <i>",
"      Bacteroides",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      Neisseria meningitidis",
"     </i>",
"     ,",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      Salmonella",
"     </i>",
"     , and",
"     <i>",
"      Rickettsia",
"     </i>",
"     ; active against many vancomycin-resistant enterococci",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F149491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Chloromycetin&reg; may be confused with chlorambucil, Chlor-Trimeton&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F149488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, delirium, depression, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, enterocolitis, glossitis, nausea, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Aplastic anemia, bone marrow suppression, granulocytopenia, hypoplastic anemia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Optic neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reactions, Gray syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chloramphenicol or any component; treatment of trivial or viral infections; bacterial prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with G-6-PD deficiency, impaired renal or hepatic function; reduce dose in patients with hepatic and renal impairment. Use in neonates and premature infants has resulted in \"gray baby syndrome\" due to immature metabolic system leading to excessive blood levels; use a reduced dose.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, and granulocytopenia) have occurred after both short-term and prolonged therapy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; monitor CBC with platelets frequently in all patients;",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     discontinue if evidence of myelosuppression.  Irreversible bone marrow suppression may occur weeks or months after therapy. Avoid repeated courses of treatment. Should not be used when less potentially toxic agents are effective; prolonged use may result in superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; breast-feeding is not recommended",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F149480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (strong), CYP2C9 (weak), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Chloramphenicol may decrease the metabolism of Anticonvulsants (Hydantoin). Anticonvulsants (Hydantoin) may decrease the serum concentration of Chloramphenicol. Increased chloramphenicol concentrations have also been seen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a strong CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyanocobalamin: Chloramphenicol may diminish the therapeutic effect of Cyanocobalamin. The expected hematologic response for the treatment of anemia may be opposed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Chloramphenicol may increase the serum concentration of CycloSPORINE (Systemic).  Management: Cyclosporine dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor cyclosporine concentrations and response closely following initiation and/or discontinuation of chloramphenicol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Strong) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Chloramphenicol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Chloramphenicol may decrease the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Chloramphenicol may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor tacrolimus concentrations and response closely following initiation and/or discontinuation of chloramphenicol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Chloramphenicol may enhance the anticoagulant effect of Vitamin K Antagonists. Chloramphenicol may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Chloramphenicol may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1046232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May decrease intestinal absorption of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     (cobalamin); may have increased dietary need for riboflavin, pyridoxine (vitamin B",
"     <sub>",
"      6",
"     </sub>",
"     ), and vitamin B",
"     <sub>",
"      12",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F149420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chloramphenicol crosses the placenta producing cord concentrations approaching maternal serum concentrations. An increased risk of teratogenic effects has not been identified for chloramphenicol and there have been no reports of fetal harm related to use of chloramphenicol in pregnancy. \"Gray Syndrome\" has occurred in premature infants and newborns receiving chloramphenicol. In most cases, chloramphenicol was started during the first 48 hours of life, but it has also occurred in older patients after high doses. Symptoms began after 3-4 days of therapy, starting with abdominal distention and continuing to progressive pallid cyanosis, vasomotor collapse, irregular respiration, and death within a few hours of symptom onset. Stopping therapy can reverse the process and allow complete recovery. There is one case report of an infant with gray baby syndrome after",
"     <i>",
"      in utero",
"     </i>",
"     exposure to a single maternal dose during labor, followed by a 10-fold overdose of chloramphenicol in the first day of life. The extent of the contribution of the single dose given during labor is unknown. The manufacturer recommends caution if used in a pregnant patient near term or during labor.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with reticulocyte and platelet counts, hematocrit, serum iron level, iron-binding capacity, periodic liver and renal function tests, serum drug concentration",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1046224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Meningitis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak: 15-25 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Trough: 5-15 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Other infections:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak: 10-20 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Trough: 5-10 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Timing of serum samples: Draw levels 0.5-1.5 hours after completion of I.V. dose",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly binds to 50S ribosomal subunits of susceptible organisms preventing amino acids from being transferred to growing peptide chains thus inhibiting protein synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Readily crosses the placenta; appears in breast milk; distributes to most tissues and body fluids; good CSF and brain penetration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CSF concentration with uninflamed meninges: 21% to 50% of plasma concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CSF concentration with inflamed meninges: 45% to 89% of plasma concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Chloramphenicol: 0.5-1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Chloramphenicol succinate: 0.2-3.1 L/kg; decreased with hepatic or renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Chloramphenicol: 60% decreased with hepatic or renal dysfunction and  30% to 40% in newborn infants",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloramphenicol succinate: Hydrolized in the liver, kidney, and lungs to chloramphenicol (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloramphenicol: Hepatic to metabolites (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloramphenicol: Oral: ~80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloramphenicol succinate: I.V.: ~70%; highly variable, dependant upon rate and extent of metabolism to chloramphenicol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-2 days: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10-16 days: 10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:  4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Normal renal function: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chloramphenicol succinate: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     End-stage renal disease: 3-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hepatic disease: Prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: ~30% as unchanged chloramphenicol succinate in urine; in infants and young children, 6% to 80% of the dose may be excreted unchanged in urine; 5% to 15% as chloramphenicol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Slightly dialyzable (5% to 20%)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1046230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content of 1 g injection: 2.25 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Three major toxicities associated with chloramphenicol include:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aplastic anemia, an idiosyncratic reaction which can occur with any route of administration; usually occurs 3 weeks to 12 months after initial exposure to chloramphenicol; incidence: 1 in 40,000 cases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bone marrow suppression is thought to be dose-related with serum concentrations &gt;25 mcg/mL and reversible once chloramphenicol is discontinued; anemia and neutropenia may occur during the first week of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gray baby syndrome is characterized by circulatory collapse, hypothermia, cyanosis, acidosis, abdominal distention, myocardial depression, coma, and death; reaction appears to be associated with serum levels &ge;50 mcg/mL; may result from drug accumulation in patients with impaired hepatic or renal function; may occur after 3-4 days of therapy or within hours of initiating therapy",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ambrose PJ, \"Clinical Pharmacokinetics of Chloramphenicol and Chloramphenicol Succinate,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1984, 9(3):222-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/35/4664/abstract-text/6375931/pubmed\" id=\"6375931\" target=\"_blank\">",
"        6375931",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Powell DA and Nahata MC, \"Chloramphenicol: New Perspectives on an Old Drug,\"",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1982, 16(4):295-300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/35/4664/abstract-text/7040026/pubmed\" id=\"7040026\" target=\"_blank\">",
"        7040026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vozeh S, Schmidlin O, and Taeschner W, \"Pharmacokinetic Drug Data,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1988, 15(4):254-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/35/4664/abstract-text/3191648/pubmed\" id=\"3191648\" target=\"_blank\">",
"        3191648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13145 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_35_4664=[""].join("\n");
var outline_f4_35_4664=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708673\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149436\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046221\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442236\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046214\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149410\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149395\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046226\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149489\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046217\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046225\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149491\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149488\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046229\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046213\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046212\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149480\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149404\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046232\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149420\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046220\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046224\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046211\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046228\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046230\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13145\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13145|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=related_link\">",
"      Chloramphenicol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/3/20532?source=related_link\">",
"      Chloramphenicol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_35_4665="Silent myocardial ischemia: Prognosis and therapy";
var content_f4_35_4665=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Silent myocardial ischemia: Prognosis and therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/35/4665/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4665/contributors\">",
"     Prakash C Deedwania, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/35/4665/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4665/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/35/4665/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4665/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/35/4665/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silent (asymptomatic) myocardial ischemia is the most common manifestation of coronary heart disease (CHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Among patients with CHD, the presence of silent ischemic episodes detected during daily life by ambulatory ECG (Holter) monitoring is predictive of an adverse clinical outcome, as evidenced by an increased risk of coronary events and cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. Treatment becomes important because most episodes of silent ischemia can be suppressed by well titrated doses of specific antiischemic drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    myocardial revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/10-14\">",
"     10-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will first review the prognostic importance of silent ischemia since it provides the rationale for both treatment and for screening. The general approach to diagnosis and screening is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28180?source=see_link\">",
"     \"Silent myocardial ischemia: Diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of silent ischemia may be viewed from the standpoint of two groups of patients: those without a history of CHD or angina pectoris; and those with a history of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients without a history of CHD, silent ischemia appears to be associated with an increased risk of adverse clinical outcomes, whether detected by exercise testing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/15-20\">",
"     15-20",
"    </a>",
"    ], office ECG in which ST-T changes may also reflect hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/21\">",
"     21",
"    </a>",
"    ], or Holter monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings. The first two studies evaluated outcomes in patients without established disease, while the latter two included patients with documented CHD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Silent ischemia is particularly important when associated with conventional risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/15-18\">",
"       15-18",
"      </a>",
"      ]. The Lipid Research Clinics Coronary Primary Prevention Trial of 3806 asymptomatic hypercholesterolemic men and the Multiple Risk Factor Intervention Trial (MRFIT) of 12,866 asymptomatic middle-aged men with two or more coronary risk factors found a significant association between exercise test-induced silent ischemia and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. In MRFIT, for example, men with exercise testing-induced silent ischemia had a relative risk of 3.4 for cardiac death compared to men without ischemic ST segment changes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A relationship between CHD risk in patients with silent ischemia and coronary risk factors was also found in a population based study that evaluated 2682 men without CHD who were followed for 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/17\">",
"       17",
"      </a>",
"      ]. Exercise-induced silent ischemia was associated with increases in mortality and the risk of any acute coronary event by 5.9- and 3-fold, respectively, in those who also smoked; by 3.8- and 1.9-fold in hypercholesterolemic subjects; and by 4.7- and 2.2-fold in hypertensive patients (",
"      <a class=\"graphic graphic_figure graphicRef56398 \" href=\"UTD.htm?21/39/22141\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/17\">",
"       17",
"      </a>",
"      ]. These associations were weaker and not significant in men without these risk factors.",
"     </li>",
"     <li>",
"      The Heart and Soul study suggests that it is the presence of ischemia, rather than that of angina, that determines outcome. In this study, the prognosis of individuals with and without inducible ischemia, as determined by treadmill stress echocardiography, and the impact of angina within either group, was evaluated in 937 patients with stable CHD [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/19\">",
"       19",
"      </a>",
"      ]. Inducible ischemia was present in 24 percent and angina was present in 17 percent. The primary outcome of myocardial infarction or CHD death at 3.9 years occurred significantly more often in patients with inducible ischemia (21 versus 8 percent without inducible ischemia). The presence of angina did not significantly affect these outcomes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Patients with chronic stable angina'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In the Psychophysiologic Investigations of Myocardial Ischemia study of 196 patients with exercise test-induced ischemia, the presence of mental stress-induced ischemia, as established by new or worsened wall motion abnormalities on radionuclide imaging, significantly predicted death during an average follow-up of 5.2 years (rate ratio 3) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patients with unstable angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silent ischemia after an episode of unstable angina has been associated with an adverse clinical outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=see_link\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, 232 patients with unstable angina had a determination of troponin T at admission and underwent 24 hour continuous ST segment monitoring with vectorcardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/23\">",
"     23",
"    </a>",
"    ]. One or more episodes of ST segment depression were independently associated with the 30 day occurrence of cardiac death or acute myocardial infarction (relative risk 7.43); elevated troponin T (&ge;0.2",
"    <span class=\"nowrap\">",
"     &micro;g/L)",
"    </span>",
"    was also associated with an increased risk (relative risk 3.85). Combining troponin T and continuous ST segment monitoring identified subgroups at high (both positive), intermediate (one positive), or low risk (neither positive) for death or myocardial infarction (25.8, 3.1, and 1.7 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patients post-MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic significance of silent ischemia is well established in survivors of MI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/7\">",
"     7",
"    </a>",
"    ]. A number of retrospective studies evaluating the role of predischarge ETT in patients with MI found that exercise-induced ischemia, regardless of associated chest pain, was predictive of an increased risk of recurrent coronary events and cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these studies generally compared the outcome of patients with and without silent ischemia determined immediately after an acute MI. In comparison, a prospective trial evaluated over 500 patients who underwent ambulatory monitoring and stress thallium scintigraphy one to six months after an acute coronary event (unstable angina or MI); silent ischemia was present in 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/24\">",
"     24",
"    </a>",
"    ]. Compared to those with symptomatic ischemia, patients with silent ischemia had less severe and extensive reversible defects on a stress thallium scan, a longer exercise duration, less frequent ST segment depression on ambulatory monitoring, and, during a 23-month follow-up, fewer recurrent cardiac events.",
"   </p>",
"   <p>",
"    Even though patients with silent ischemia are at less risk than symptomatic patients, silent ischemia within a few weeks post-MI (as detected by Holter monitoring) is associated with a two- to fourfold increase in cardiac event rates during follow-up compared to those without evidence of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/4,5,7\">",
"     4,5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Patients with chronic stable angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased risk of coronary events and cardiac mortality in association with silent ischemia has been extensively documented in patients with stable CHD (",
"    <a class=\"graphic graphic_table graphicRef67639 \" href=\"UTD.htm?26/30/27116\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/1,6,9\">",
"     1,6,9",
"    </a>",
"    ]. As an example, silent ischemia during ambulatory monitoring in studies of patients with stable angina (many of whom were symptom free) was associated with a higher risk for coronary events and cardiac mortality&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/6,25\">",
"     6,25",
"    </a>",
"    ]. Multiple regression analyses comparing several established clinical, ECG, and exercise test parameters revealed that silent ischemia during ambulatory monitoring was the most powerful, and independent predictor of adverse clinical outcome and cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/6\">",
"     6",
"    </a>",
"    ]. The Angina Prognosis Study in Stockholm (APSIS) of 686 patients found that ambulatory ischemia, especially when present for &ge;30 minutes during a 24 hour period, was independently associated with cardiovascular death only in patients with &ge;2 mm ST segment depression during exercise testing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/26\">",
"     26",
"    </a>",
"    ]. This suggests that ambulatory monitoring and exercise testing provide complementary information among patients with marked ischemia during exercise.",
"   </p>",
"   <p>",
"    A report of 558 patients from the NIH-sponsored Asymptomatic Cardiac Ischemia Pilot (ACIP) trial noted that death, myocardial infarction, or hospitalization occurred in 13 percent of patients with silent ischemia within 12 months. Multivariate analysis indicated that only the number of ischemic episodes on the entry ambulatory ECG monitor predicted outcome, although the effect was small (odds ratio 1.06)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/27\">",
"     27",
"    </a>",
"    ]. An angiographic study from the same trial found no correlation between the severity of coronary disease or the presence of a complex plaque and adverse outcome at 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of ischemia as a predictor of outcome in patients with chronic stable angina was also demonstrated in the Heart and Soul study discussed above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Asymptomatic patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mechanisms related to adverse prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise reason for the adverse prognosis associated with silent ischemia is not known. Hypotheses center around abnormalities seen on myocardial biopsy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Animal models have shown that repeated episodes of transient myocardial ischemia are associated with small but distinct areas of subendocardial necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies in humans have demonstrated that myocardial hypokinesia is associated with abnormalities of nuclei and mitochondria, loss of myocytes, and increased interstitial fibrosis in the subendocardial areas on myocardial biopsies (obtained during surgery) from areas supplied by diseased coronary arteries [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/30\">",
"       30",
"      </a>",
"      ]. These changes were seen in the absence of any gross histologic evidence of MI.",
"     </li>",
"     <li>",
"      Structural alterations of the myocardium (hypertrophy and increased interstitial nonmuscular tissue) appear to be associated with evidence of ischemia-induced regional wall motion abnormalities during exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, it is possible that repeated episodes of silent ischemia could lead to progressive fibrosis and the development of left ventricular dysfunction. It is also conceivable that prolonged episodes of silent ischemia lead to life-threatening arrhythmias, especially in patients with an electrical substrate for arrhythmias.",
"   </p>",
"   <p>",
"    The rationale for treatment of silent ischemia is based upon the preceding observations of an increase in cardiovascular risk. The approach to therapy includes consideration of three questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What are the available methods for treatment?",
"     </li>",
"     <li>",
"      Are the available methods effective in suppressing ischemia?",
"     </li>",
"     <li>",
"      Does suppression of ischemia improve clinical outcome?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT WITHOUT REVASCULARIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently no ideal therapy for silent ischemia, although several options are available [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/2\">",
"     2",
"    </a>",
"    ]. The ideal approach for any disorder should be based upon its underlying pathophysiology. Increased myocardial oxygen demand appears to be the primary reason for the development of silent ischemia. Thus, beta blockers and heart rate reducing calcium channel blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ) are the logical therapeutic agents since these drugs decrease myocardial oxygen demand. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42135?source=see_link\">",
"     \"Silent myocardial ischemia: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The elimination of ST segment depression on Holter monitoring is frequently used to evaluate the effect of these therapies; however, the marked variability in the number and duration of ischemic episodes as detected with this technique may confound the accurate assessment of prescribed therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although all antianginal drugs have been shown to reduce silent ischemia, beta blockers appear to be most effective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. One crossover trial in 24 patients, for example, found that both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    reduced the frequency and duration of transient silent ischemic events (",
"    <a class=\"graphic graphic_figure graphicRef75587 \" href=\"UTD.htm?7/21/7518\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/11\">",
"     11",
"    </a>",
"    ]. However, atenolol was more effective and only atenolol produced a reduction in the average duration of silent ischemia per patient in the high-risk period between 6 AM and 12 PM (139 versus 1609 sec).",
"   </p>",
"   <p>",
"    Furthermore, only beta blockers appear to reduce the adverse outcome associated with silent ischemia. The multicenter",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     Atenolol",
"    </a>",
"    Silent Ischemia Trial (ASIST) evaluated 306 patients with mild or no angina and evidence of silent ischemia on ETT and ambulatory monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/13\">",
"     13",
"    </a>",
"    ]. The patients were randomly assigned to atenolol 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or placebo. After four weeks, atenolol therapy was associated with the following benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in the number (3.6 to 1.7 versus 4.4 to 3.1 with placebo) and duration (30 to 16.4 versus 37 to 30 minutes) of ischemic episodes per 48 hours on ambulatory monitoring.",
"     </li>",
"     <li>",
"      A prolonged event-free survival and an increased time to first event (120 versus 79 days.)",
"     </li>",
"     <li>",
"      There was a nonsignificant trend for fewer serious events (death, resuscitated ventricular tachycardia or fibrillation, nonfatal myocardial infarction, or hospitalization for unstable angina.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Beta blockers also have several other potential advantages including lowering the blood pressure and efficacy in secondary prevention after an acute myocardial infarction.",
"   </p>",
"   <p>",
"    Thus, beta blockers should be considered first-line therapy for silent ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. The antiischemic efficacy of beta blockers can be evaluated by repeating Holter monitoring and titrating the dose until the ischemia is suppressed by at least 50 percent or the maximum tolerated dose is reached.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although beta blockers produce the greatest reduction in the number and duration of ischemic episodes, calcium channel blockers are also effective. Calcium channel blockers may be particularly effective when silent ischemia occurs without an increase in heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/33\">",
"     33",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     Amlodipine",
"    </a>",
"    , long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    and short- and long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    reduce ischemic episodes by 13 to 69 percent, and decrease ischemia duration by 6 to 68 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/10,11,33-38\">",
"     10,11,33-38",
"    </a>",
"    ]. One study of 68 patients, for example, found that long-acting diltiazem (480",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    administered either in the morning or evening, reduced the duration and number of episodes of myocardial ischemia by 45 and 40 percent, respectively, as compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Drug combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination drug therapy is necessary when monotherapy with beta blockers does not effectively suppress silent ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. Combined therapy can also be used to lower the dose of medications, thereby decreasing dose-related side effects and improving compliance. Ideally, the best combination consists of drugs that cancel or dampen the undesirable actions of each other, and prevent any increase in myocardial oxygen demand. One of the most favored combinations consists of a long-acting nitrate preparation (using a regimen that avoids nitrate tolerance) and a long-acting beta blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/12\">",
"     12",
"    </a>",
"    ]. A long-acting dihydropyridine and a beta blocker together are also effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=see_link\">",
"     \"Nitrates in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When beta blockers cannot be used because of obvious intolerance or contraindication, a suitable alternative is the combination of a calcium blocker and a long-acting nitrate. Although all calcium blockers have some efficacy in reducing silent ischemia, the agents without propensity to reflex tachycardia (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ) are preferred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=see_link\">",
"     \"Major side effects and safety of calcium channel blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Total suppression of ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The worse prognosis of patients with silent myocardial ischemia led to the concept of the suppression of total ischemic burden, regardless of whether ischemia is painful or silent. The evidence indicating that complete suppression of ischemia with aggressive antiischemic drug therapy could improve the adverse clinical outcomes associated with silent ischemia is not strong [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a few well-controlled, randomized, large-scale trials have evaluated the impact of Holter guided antiischemic therapy on the frequency and duration of ischemic episodes during daily life [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/12-14,34,39\">",
"     12-14,34,39",
"    </a>",
"    ]. Some of these studies have also evaluated, on a limited basis, the implications of ischemia guided therapy on the clinical outcome in patients with stable CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As noted above, the ASIST trial showed that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      was associated with a longer event-free survival than placebo (120 versus 79 days, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results have been reported in another large study from Europe, the Total Ischemic Burden",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"       Bisoprolol",
"      </a>",
"      Study (TIBBS), in which the beta blocker bisoprolol was found to be more effective than sustained release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      in suppressing silent ischemia and in improving the clinical outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/34\">",
"       34",
"      </a>",
"      ]. Patients who had more than 50 percent suppression of silent ischemia (defined as a 100 percent responder) had a significantly better outcome as denoted by event-free survival during the one year follow-up period (",
"      <a class=\"graphic graphic_figure graphicRef55720 \" href=\"UTD.htm?17/55/18301\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The ACIP study found that, among the medically treated patients, a trend toward a reduced incidence of combined cardiac events at one year in association with a greater reduction in Holter ischemic episodes and an increased duration of exercise in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment with revascularization'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stress reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mental stress can provoke silent ischemia, especially in patients with underlying coronary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42135?source=see_link\">",
"     \"Silent myocardial ischemia: Epidemiology and pathogenesis\"",
"    </a>",
"    .) There are limited data supporting a possible benefit of stress reduction as a form of therapy in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report of 107 patients with coronary artery disease and ischemia documented with mental stress or on ambulatory monitoring found that compared to usual care, a four month program of stress management reduced the frequency of ischemic episodes, particularly among those patients with a higher frequency of ischemic episodes (&ge;4) in baseline; there was no significant effect seen with exercise management&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study randomly assigned 94 patients with ischemia on monitoring or with mental stress to four months of weekly stress management classes, aerobic exercise (three times per week), or usual care [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/43\">",
"       43",
"      </a>",
"      ]. Patients undergoing stress management had a significantly lower number of coronary events at two years (10 versus 17 and 30 for exercise and usual care.) This was associated with significantly lower costs for medical care.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Statin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperlipidemia is associated with endothelial dysfunction, which promotes the development of atherosclerosis and also can cause unopposed vasoconstriction at established coronary stenoses, thereby triggering silent or overt ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link\">",
"     \"Endothelial dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One controlled study evaluated the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    compared to placebo in ameliorating ST segment depression in 40 patients with established coronary artery disease, total serum cholesterol levels between 190 and 330",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.9 and 8.6",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and at least one minute of ST segment depression during 48 hours of ambulatory monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/45\">",
"     45",
"    </a>",
"    ]. At six months, active therapy significantly reduced the number of episodes of ST segment depression and abolished ST segment depression in a higher percentage of patients (65 versus 10 percent in the placebo group).",
"   </p>",
"   <p>",
"    A large prospective randomized study compared the efficacy of intensive lipid lowering therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80mg daily with moderate lipid lowering therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    40 mg daily in 893 elderly patients (mean age 73 years) with CAD and at least one episode of myocardial ischemia that lasted at least three minutes on 48 hours ambulatory ECG monitoring while continuing their prescribed anti-anginal drugs. Compared to the baseline, repeat evaluations at 3 and 12 months ambulatory ECG monitorings showed significant reductions in the number and duration of myocardial ischemia with both treatment strategies. Although there was no significant difference in the efficacy of the two treatment strategies on myocardial ischemia, the intensive lipid lowering therapy group receiving atorvastatin 80 mg daily had fewer major acute cardiovascular events and death during the 12 months' follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT WITH REVASCULARIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data evaluating the efficacy of coronary revascularization in the treatment of silent ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/12,14,47,48\">",
"     12,14,47,48",
"    </a>",
"    ]. However, the available data suggest that revascularization may improve patient outcomes.",
"   </p>",
"   <p>",
"    The potential benefit of revascularization was illustrated in the NIH-sponsored Asymptomatic Cardiac Ischemia Pilot (ACIP) study, which randomly assigned 558 patients to one of three treatment strategies: medical therapy guided by angina relief, medical therapy guided by absence of ischemia on Holter monitoring, or revascularization with PTCA or CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Medical therapy included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    plus sustained release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    if needed plus sustained release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    if needed.",
"   </p>",
"   <p>",
"    The primary findings of this pilot trial with a relatively small number of patients and events were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 12 weeks, CABG more effectively suppressed ischemia than PTCA both on the ambulatory ECG (70 versus 46 percent of patients) and on ETT (46 versus 23 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mortality at one and two years was lower for patients undergoing revascularization compared to those with Holter guided therapy or medical therapy guided by relief of angina (0 versus 1.6 and 4.4 percent, respectively, at one year, and 1.1 versus 4.4 and 6.6 percent, respectively, at two years). There was no significant difference between the two medical therapy strategies (",
"      <a class=\"graphic graphic_figure graphicRef74612 graphicRef65904 \" href=\"UTD.htm?33/8/33920\">",
"       figure 4A-B",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/14,48\">",
"       14,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rates for the combined end points of death, myocardial infarction, or recurrent hospitalization at one and two years were lower for patients undergoing revascularization compared with those undergoing either form of medical therapy. There was no significant difference between the two medical treatments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the results suggested that surgical revascularization was more effective than PTCA or medical therapy in suppressing myocardial ischemia and improving clinical outcome, drug therapies were not optimized and may have minimized the efficacy of medical therapy in improving the clinical outcome.",
"   </p>",
"   <p>",
"    The lack of optimal medical therapy is not a trivial issue. Among patients with stable angina at increased risk, initial trials suggested better outcomes with PCI. Of greater relevance is the COURAGE trial published in 2007, which compared optimal medical therapy alone (both antianginal drugs and aggressive secondary prevention) to optimal medical therapy plus PCI with bare metal stents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/49\">",
"     49",
"    </a>",
"    ]. There was no difference between the groups in the primary end point of death from any cause and non-fatal MI at 4.6 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link&amp;anchor=H13#H13\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\", section on 'COURAGE and FAME II trials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Post-MI ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of silent ischemia soon after myocardial infarction has not been determined. The best data come from two randomized trials: DANAMI and SWISSI II, both of which showed better outcomes with PCI compared to medical therapy. However, neither trial used current optimal medical therapy or optimal interventional therapy. As demonstrated in the COURAGE trial cited above, optimal medical therapy may abolish many of the benefits of revascularization seen in earlier trials [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The DANAMI trial, in which patients were enrolled in the early 1990s, compared conservative medical therapy to revascularization in patients with post-MI ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/50\">",
"     50",
"    </a>",
"    ]. In this trial, approximately 1000 patients treated with a fibrinolytic agent developed either spontaneous symptomatic angina (44 percent) or inducible post-MI silent ischemia on a predischarge exercise test (56 percent). The patients were randomly assigned to conservative therapy or revascularization with PCI or CABG two to ten weeks after the MI.",
"   </p>",
"   <p>",
"    At one, two, and four years, the primary end points (mortality, reinfarction, or admission for unstable angina) occurred less frequently in the invasive group compared to those treated conservatively (15 versus 30 percent, 24 versus 37 percent, and 32 versus 44 percent, respectively). The benefit was due to reductions in reinfarction and admission for unstable angina since mortality after a median follow-up of 2.4 years was the same in both groups (3.6 versus 4.4 percent). Data on outcomes limited to patients with silent ischemia were not presented.",
"   </p>",
"   <p>",
"    The optimal management of asymptomatic post-MI patients who are found to have inducible ischemia on stress testing has not been well studied. In the first long-term randomized trial addressing this issue, SWISSI II recruited 201 patients with a first ST segment elevation or a non-ST segment elevation MI who, within the first three months (but mostly in the first two weeks), had silent ischemia on stress imaging and documentation of one or two vessel coronary artery disease suitable for PTCA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/51\">",
"     51",
"    </a>",
"    ]. Approximately 90 percent were treated with thrombolytic therapy.",
"   </p>",
"   <p>",
"    The patients, who were recruited between 1991 and 1997, were randomly assigned to either PCI (including PTCA) or medical management with an intensive anti-ischemic regimen (beta blocker,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nitrates). The aim in the interventional group was complete revascularization and the aim in the medical group was maximal reduction in silent ischemia during exercise testing. Both groups were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a statin.",
"   </p>",
"   <p>",
"    At a mean follow-up of 10.2 years, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary combined end point of cardiac death, nonfatal MI ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptom driven revascularization occurred significantly less often in the PCI group (3.2 versus 9.5 percent; adjusted hazard ratio 0.33, 95% CI 0.20-0.55).",
"     </li>",
"     <li>",
"      Left ventricular ejection fraction remained unchanged in the PCI group, but fell significantly in the medical group (54 and 55 versus 51 and 49 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with postinfarction angina have a worse prognosis than those without it [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/52\">",
"     52",
"    </a>",
"    ] and the above data suggest that patients with silent ischemia may have a worse outcome with medical therapy compared to PTCA, with the caveat that these studies were performed in early and mid 1990s, before optimal medical therapy had been defined.",
"   </p>",
"   <p>",
"    All patients with acute MI are now treated with optimal medical therapy. Stress testing in asymptomatic patients after acute MI is only performed in those who have not been fully revascularized. Among such patients who are found to have asymptomatic ischemia, there are no clear criteria to determine which patients will undergo revascularization. We suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary angiography followed by revascularization if appropriate is performed in patients with noninvasive evidence of suggesting a moderate to large amount of myocardium at risk. Examples include ischemia during stage I or II of the Bruce protocol, a hypotensive blood pressure response or symptoms of pulmonary congestion, more than 2 mm of ST segment depression, or imaging studies suggesting involvement of either a large portion of the anterior wall or showing multiple areas of ischemia.",
"     </li>",
"     <li>",
"      Patients with only mild ischemia can be continued on medical therapy alone, but patient preference may be important.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach is consistent with the recommendations for the management of asymptomatic ischemia or mild angina in the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA/SCAI",
"    </span>",
"    guideline update on PCI (no change was made in the 2007 focused update) and the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guideline update on CABG in patients with asymptomatic myocardial ischemia (",
"    <a class=\"graphic graphic_table graphicRef69950 \" href=\"UTD.htm?10/44/10956\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4665/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109072387\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of silent ischemia is associated with a poorer prognosis. Several studies have demonstrated that even in asymptomatic patients (with no prior history of coronary heart disease [CHD]) silent ischemia detected by ECG or myocardial imaging during stress testing identifies a higher risk cohort at increased risk of coronary events and cardiac death. Most studies conducted during the past three decades have assessed the prognostic importance of silent ischemia in patients with established CHD with stable angina and acute coronary syndromes. In these studies, the presence of silent ischemia detected during ambulatory ECG monitoring or stress testing was associated with an increased risk of cardiac events and cardiac death.",
"   </p>",
"   <p>",
"    There is no ideal or specific treatment for silent ischemia. In general, the therapeutic approach should be based on an underlying pathophysiologic basis, and as such, in most patients it should consist of beta-blockers and other heart rate reducing agents. Vasodilators such as long acting nitrates should also be considered in those not responding to heart rate reducing therapy alone. Most patients with silent ischemia will require combination therapy with multiple medications. When anti-ischemic drug therapy is not effective in suppressing myocardial ischemia, revascularization should be considered. Whether total suppression of myocardial ischemia is necessary or useful in improving the adverse prognosis associated with silent ischemia is still a subject of considerable debate and needs further evaluation by randomized controlled trials.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/1\">",
"      Deedwania PC, Carbajal EV. Silent myocardial ischemia. A clinical perspective. Arch Intern Med 1991; 151:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/2\">",
"      Kaski JC, Cos&iacute;n Sales J, Arroyo Espliguero R. Silent myocardial ischaemia: clinical relevance and treatment. Expert Opin Investig Drugs 2005; 14:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/3\">",
"      Gottlieb SO, Weisfeldt ML, Ouyang P, et al. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med 1986; 314:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/4\">",
"      Gottlieb SO, Gottlieb SH, Achuff SC, et al. Silent ischemia on Holter monitoring predicts mortality in high-risk postinfarction patients. JAMA 1988; 259:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/5\">",
"      Tzivoni D, Gavish A, Zin D, et al. Prognostic significance of ischemic episodes in patients with previous myocardial infarction. Am J Cardiol 1988; 62:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/6\">",
"      Deedwania PC, Carbajal EV. Silent ischemia during daily life is an independent predictor of mortality in stable angina. Circulation 1990; 81:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/7\">",
"      Deedwania PC. Asymptomatic ischemia during predischarge Holter monitoring predicts poor prognosis in the postinfarction period. Am J Cardiol 1993; 71:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/8\">",
"      Deedwania PC. Silent ischemia predicts poor outcome in high-risk healthy men. J Am Coll Cardiol 2001; 38:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/9\">",
"      Yeung AC, Barry J, Orav J, et al. Effects of asymptomatic ischemia on long-term prognosis in chronic stable coronary disease. Circulation 1991; 83:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/10\">",
"      Stone PH, Gibson RS, Glasser SP, et al. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group. Circulation 1990; 82:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/11\">",
"      Deedwania PC, Carbajal EV, Nelson JR, Hait H. Anti-ischemic effects of atenolol versus nifedipine in patients with coronary artery disease and ambulatory silent ischemia. J Am Coll Cardiol 1991; 17:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/12\">",
"      Knatterud GL, Bourassa MG, Pepine CJ, et al. Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) study. J Am Coll Cardiol 1994; 24:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/13\">",
"      Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 1994; 90:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/14\">",
"      Rogers WJ, Bourassa MG, Andrews TC, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study: outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. The ACIP Investigators. J Am Coll Cardiol 1995; 26:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/15\">",
"      Exercise electrocardiogram and coronary heart disease mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Am J Cardiol 1985; 55:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/16\">",
"      Ekelund LG, Suchindran CM, McMahon RP, et al. Coronary heart disease morbidity and mortality in hypercholesterolemic men predicted from an exercise test: the Lipid Research Clinics Coronary Primary Prevention Trial. J Am Coll Cardiol 1989; 14:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/17\">",
"      Laukkanen JA, Kurl S, Lakka TA, et al. Exercise-induced silent myocardial ischemia and coronary morbidity and mortality in middle-aged men. J Am Coll Cardiol 2001; 38:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/18\">",
"      Gibbons LW, Mitchell TL, Wei M, et al. Maximal exercise test as a predictor of risk for mortality from coronary heart disease in asymptomatic men. Am J Cardiol 2000; 86:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/19\">",
"      Gehi AK, Ali S, Na B, et al. Inducible ischemia and the risk of recurrent cardiovascular events in outpatients with stable coronary heart disease: the heart and soul study. Arch Intern Med 2008; 168:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/20\">",
"      Sheps DS, McMahon RP, Becker L, et al. Mental stress-induced ischemia and all-cause mortality in patients with coronary artery disease: Results from the Psychophysiological Investigations of Myocardial Ischemia study. Circulation 2002; 105:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/21\">",
"      Sigurdsson E, Sigfusson N, Sigvaldason H, Thorgeirsson G. Silent ST-T changes in an epidemiologic cohort study--a marker of hypertension or coronary heart disease, or both: the Reykjavik study. J Am Coll Cardiol 1996; 27:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/22\">",
"      Sajadieh A, Nielsen OW, Rasmussen V, et al. Prevalence and prognostic significance of daily-life silent myocardial ischaemia in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 2005; 26:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/23\">",
"      N&oslash;rgaard BL, Andersen K, Dellborg M, et al. Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring. TRIM study group. Thrombin Inhibition in Myocardial Ischemia. J Am Coll Cardiol 1999; 33:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/24\">",
"      Narins CR, Zareba W, Moss AJ, et al. Clinical implications of silent versus symptomatic exercise-induced myocardial ischemia in patients with stable coronary disease. J Am Coll Cardiol 1997; 29:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/25\">",
"      Deedwania PC, Carbajal EV. Prevalence and patterns of silent myocardial ischemia during daily life in stable angina patients receiving conventional antianginal drug therapy. Am J Cardiol 1990; 65:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/26\">",
"      Forslund L, Hjemdahl P, Held C, et al. Prognostic implications of ambulatory myocardial ischemia and arrhythmias and relations to ischemia on exercise in chronic stable angina pectoris (the Angina Prognosis Study in Stockholm [APSIS]). Am J Cardiol 1999; 84:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/27\">",
"      Pepine CJ, Sharaf B, Andrews TC, et al. Relation between clinical, angiographic and ischemic findings at baseline and ischemia-related adverse outcomes at 1 year in the Asymptomatic Cardiac Ischemia Pilot study. ACIP Study Group. J Am Coll Cardiol 1997; 29:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/28\">",
"      Sharaf BL, Williams DO, Miele NJ, et al. A detailed angiographic analysis of patients with ambulatory electrocardiographic ischemia: results from the Asymptomatic Cardiac Ischemia Pilot (ACIP) study angiographic core laboratory. J Am Coll Cardiol 1997; 29:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/29\">",
"      Geft IL, Fishbein MC, Ninomiya K, et al. Intermittent brief periods of ischemia have a cumulative effect and may cause myocardial necrosis. Circulation 1982; 66:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/30\">",
"      Schaper J. Effects of multiple ischaemic events on human myocardium--an ultrastructural study. Eur Heart J 1988; 9 Suppl A:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/31\">",
"      Hess OM, Schneider J, Nonogi H, et al. Myocardial structure in patients with exercise-induced ischemia. Circulation 1988; 77:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/32\">",
"      Patel DJ, Mulcahy D, Norrie J, et al. Natural variability of transient myocardial ischaemia during daily life: an obstacle when assessing efficacy of anti-ischaemic agents? Heart 1996; 76:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/33\">",
"      Andrews TC, Fenton T, Toyosaki N, et al. Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation 1993; 88:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/34\">",
"      Von Arnim T. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up. J Am Coll Cardiol 1996; 28:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/35\">",
"      Th&eacute;roux P, Baird M, Juneau M, et al. Effect of diltiazem on symptomatic and asymptomatic episodes of ST segment depression occurring during daily life and during exercise. Circulation 1991; 84:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/36\">",
"      Davies RF, Habibi H, Klinke WP, et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. J Am Coll Cardiol 1995; 25:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/37\">",
"      Kawanishi DT, Reid CL, Morrison EC, Rahimtoola SH. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol 1992; 19:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/38\">",
"      Deedwania PC, Pool PE, Thadani U, Eff J. Effect of morning versus evening dosing of diltiazem on myocardial ischemia detected by ambulatory electrocardiographic monitoring in chronic stable angina pectoris. Dilacor XR Ambulatory Ischemia Study Group. Am J Cardiol 1997; 80:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/39\">",
"      Deedwania PC. Is there evidence in support of the ischemia suppression hypothesis? J Am Coll Cardiol 1994; 24:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/40\">",
"      Stone PH, Chaitman BR, Forman S, et al. Prognostic significance of myocardial ischemia detected by ambulatory electrocardiography, exercise treadmill testing, and electrocardiogram at rest to predict cardiac events by one year (the Asymptomatic Cardiac Ischemia Pilot [ACIP] study). Am J Cardiol 1997; 80:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/41\">",
"      Friedman M, Breall WS, Goodwin ML, et al. Effect of type A behavioral counseling on frequency of episodes of silent myocardial ischemia in coronary patients. Am Heart J 1996; 132:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/42\">",
"      Blumenthal JA, Jiang W, Babyak MA, et al. Stress management and exercise training in cardiac patients with myocardial ischemia. Effects on prognosis and evaluation of mechanisms. Arch Intern Med 1997; 157:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/43\">",
"      Blumenthal JA, Babyak M, Wei J, et al. Usefulness of psychosocial treatment of mental stress-induced myocardial ischemia in men. Am J Cardiol 2002; 89:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/44\">",
"      Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/45\">",
"      Andrews TC, Raby K, Barry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997; 95:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/46\">",
"      Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007; 115:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/47\">",
"      Bourassa MG, Pepine CJ, Forman SA, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study: effects of coronary angioplasty and coronary artery bypass graft surgery on recurrent angina and ischemia. The ACIP investigators. J Am Coll Cardiol 1995; 26:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/48\">",
"      Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997; 95:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/49\">",
"      Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/50\">",
"      Madsen JK, Grande P, Saunam&auml;ki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation 1997; 96:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/51\">",
"      Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA 2007; 297:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/52\">",
"      Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007) www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4665/abstract/54\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     King SB, 3rd, Smith, SC Jr, Hirshfeld, JW Jr, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008; 117:261. Available at: www.circ.ahajournals.org (accessed January 29, 2008).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1485 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_35_4665=[""].join("\n");
var outline_f4_35_4665=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H109072387\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patients with unstable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patients post-MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Patients with chronic stable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mechanisms related to adverse prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT WITHOUT REVASCULARIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Drug combinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Total suppression of ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stress reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Statin therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT WITH REVASCULARIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Post-MI ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109072387\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1485\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1485|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/39/22141\" title=\"figure 1\">",
"      Silent ischemia CHD mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/21/7518\" title=\"figure 2\">",
"      Drug Rx in silent ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/55/18301\" title=\"figure 3\">",
"      Event suppression with Rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/59/41918\" title=\"figure 4A\">",
"      Revascular silent ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/14/21742\" title=\"figure 4B\">",
"      Revascular in silent ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1485|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/30/27116\" title=\"table 1\">",
"      Noninvasive risk stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/44/10956\" title=\"table 2\">",
"      ACC AHA CABG asx CAD mild AP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=related_link\">",
"      Nitrates in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=related_link\">",
"      Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28180?source=related_link\">",
"      Silent myocardial ischemia: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42135?source=related_link\">",
"      Silent myocardial ischemia: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_35_4666="Emergency department evaluation of acute onset psychosis in children";
var content_f4_35_4666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emergency department evaluation of acute onset psychosis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/35/4666/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4666/contributors\">",
"     Kavita M Babu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4666/contributors\">",
"     Edward W Boyer, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/35/4666/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4666/contributors\">",
"     Stephen J Teach, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4666/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/35/4666/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/35/4666/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/35/4666/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;New-onset psychosis in children and adolescents represents an uncommon and complex presenting complaint. Psychosis has been defined as a \"disruption in thinking, accompanied by delusions or hallucinations\" [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/1\">",
"     1",
"    </a>",
"    ]. Delusions represent false, fixed beliefs that cannot be resolved through logical argument, while hallucinations are false perceptions that have no basis in external stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, delirium is marked by an altered sensorium with waxing and waning deficits in attention and concentration. Orientation and concentration are preserved with functional psychosis. However, the distinction between delirium and psychosis in pediatric patients can be difficult to establish, particularly in younger children. Despite these differences, hallucinations may actually represent a symptom of delirium, and separating psychosis and delirium acutely may be impossible.",
"   </p>",
"   <p>",
"    The onset of psychosis is an important diagnostic element. Acute onset occurs more commonly with an underlying medical cause rather than psychiatric disease. Even patients with symptoms suggestive of a primary psychiatric diagnosis should undergo a medical evaluation to exclude possible reversible etiologies of psychosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of psychosis in children encompasses hypoglycemia, cerebral hypoxia, drug toxicity, medical illness, and psychiatric disease (",
"    <a class=\"graphic graphic_table graphicRef52785 \" href=\"UTD.htm?24/61/25564\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50275 \" href=\"UTD.htm?25/40/26251\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Substrate deficiency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hypoglycemia",
"      </strong>",
"      &ndash; Hypoglycemia is a rare, but important cause of psychosis and hallucinations [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. All patients with alterations in mental status require immediate bedside capillary glucose testing. Rapid correction of blood sugar is critical to prevent seizures and persistent neurologic sequelae. Hypoglycemia with abrupt change in behavior may occur in children being treated for Type I and Type II diabetes; alternatively, hypoglycemia may result from ingestions (eg, ethanol, beta-blockers, and sulfonylureas) or from inborn errors of metabolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link\">",
"       \"Approach to hypoglycemia in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cerebral hypoxia",
"      </strong>",
"      &ndash; Inadequate brain oxygenation may lead to altered mental status with combative behavior. Thus, any condition that results in hypoxemia (eg, pulmonary insufficiency), insufficient oxygen carrying capacity of the blood (eg, severe anemia), or inadequate brain perfusion (eg, cardiac insufficiency) may result in an encephalopathy with psychotic features. These patients require emergent identification of the underlying cause of cerebral hypoxia and immediate interventions to restore brain oxygenation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Drug toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug exposures are a common cause of delirium, delusions,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psychosis, especially in the adolescent population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Drug overdose or abuse",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Anticholinergic toxicity",
"      </strong>",
"      &ndash; Mental status changes from central anticholinergic effects may occur with few if any peripheral signs. Anticholinergic toxicity can cause psychosis in both children and adolescents. Common anticholinergic medications include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/9/34960?source=see_link\">",
"       scopolamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/15/11509?source=see_link\">",
"       dimenhydrinate",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/52/25413?source=see_link\">",
"       chlorpheniramine",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/7/26741?source=see_link\">",
"       hyoscyamine",
"      </a>",
"      , and symptoms may occur even at standard therapeutic dosages [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/4\">",
"       4",
"      </a>",
"      ]. Typical and atypical antipsychotic medications also have anticholinergic activity and can produce anticholinergic toxicity in overdose. Recreational use of anticholinergic medications and plants (eg, Datura stramonium [Jimson weed], Datura inoxia [Moonflower], Brugmansia species [Angel's trumpet]) with severe psychotic symptoms, including paranoia, delusions of persecution, and visual hallucinations has been reported among adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/5\">",
"       5",
"      </a>",
"      ]. Other signs of anticholinergic toxicity include, mydriasis, dry mucus membranes, lack of diaphoresis, urinary retention, decreased bowel sounds, hypertension, tachycardia, and hyperthermia (",
"      <a class=\"graphic graphic_table graphicRef71268 \" href=\"UTD.htm?43/6/44140\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=see_link\">",
"       \"Anticholinergic poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Sympathomimetic toxicity",
"      </strong>",
"      &ndash; A wide range of sympathomimetic substances, including",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/8/20613?source=see_link\">",
"       pseudoephedrine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/7/6263?source=see_link\">",
"       dextroamphetamine",
"      </a>",
"      , MDMA (\"ecstasy\"), amphetamine, methamphetamine, and cocaine have been associated with psychosis in children [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/6-9\">",
"       6-9",
"      </a>",
"      ]. While these substances exacerbate existing psychosis in patients with psychiatric disease, they may also produce new psychotic symptoms in patients with no prior history of mental illness [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/6\">",
"       6",
"      </a>",
"      ]. Psychosis from sympathomimetic agents is typically accompanied by characteristic findings of hypertension, tachycardia, hyperthermia, mydriasis, and diaphoresis (",
"      <a class=\"graphic graphic_table graphicRef71268 \" href=\"UTD.htm?43/6/44140\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"       \"Cocaine: Acute intoxication\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=see_link\">",
"       \"Methamphetamine intoxication\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=see_link\">",
"       \"MDMA (ecstasy) intoxication\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hallucinogens",
"      </strong>",
"      &ndash; Adolescents may intentionally experiment with these agents to experience hallucinations, while young children may come into contact with them unintentionally. Commonly abused agents include lysergic acid diethylamide (LSD), phencyclidine (PCP),",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/21/34132?source=see_link\">",
"       dextromethorphan",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      , and salvia divinorum.",
"      <br/>",
"      <br/>",
"      LSD remains the prototypical hallucinogen and the most extensively studied of such drugs. LSD users report a wide variety of neuropsychiatric symptoms, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Distortions of time perception",
"     </li>",
"     <li>",
"      Visual illusions (eg, unusually vivid or distorted objects and intense colors)",
"     </li>",
"     <li>",
"      Euphoria and feelings of expansiveness",
"     </li>",
"     <li>",
"      Depersonalization",
"     </li>",
"     <li>",
"      Blending of the senses (synesthesia)",
"      <br/>",
"      <br/>",
"      While intoxicated, most individuals remain oriented and aware that their experiences are drug-induced. Signs of sympathetic stimulation are common but generally mild, and may include tachycardia, hypertension, mydriasis, piloerection, and diaphoresis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44584?source=see_link\">",
"       \"Intoxication from LSD and other common hallucinogens\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/21/34132?source=see_link\">",
"       Dextromethorphan",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      , and phencyclidine (PCP) belong to a class of hallucinogens known as dissociative agents that act as antagonists at the N-methyl-D-aspartate (NMDA) receptor; NMDA receptor hypofunction has been postulated as one neurochemical mechanism of psychosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44584?source=see_link\">",
"       \"Intoxication from LSD and other common hallucinogens\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Dextromethorphan is the most widely available of the dissociative agents, and its recreational misuse is growing among adolescents. Patients intoxicated with dextromethorphan may display euphoria, tachycardia, diaphoresis, hallucinations, agitation, and hyperthermia. Frank psychosis due to dextromethorphan has also been reported. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17353?source=see_link\">",
"       \"Dextromethorphan poisoning: Epidemiology, pharmacology and clinical features\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Initially developed as a field anesthetic for military purposes, ketamine has been a widely used recreational drug since the 1970s. Ketamine abuse is closely associated worldwide with the use of other \"club drugs\" including \"ecstasy\" (3,4-methylenedioxymethamphetamine or MDMA), gamma hydroxybutyrate (GHB), and methamphetamine, often in the setting of large dance parties known as raves. Ketamine produces visual and auditory hallucinations. In addition, ketamine may cause nystagmus, hyperthermia, hypertension, and tachycardia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40935?source=see_link\">",
"       \"Ketamine poisoning\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Phencyclidine (PCP) can induce acute schizophrenia in adolescents, including agitation, memory loss, psychosis, audio-visual hallucinations, and paranoid delusions. Acute brain syndrome, characterized by confusion, disorientation, poor judgment, and amnesia is seen in approximately one third of patients. Recovery from psychosis can take weeks to months. Other clinical features include horizontal, vertical, or rotatory nystagmus, violent behavior, and decreased pain response. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/35/570?source=see_link\">",
"       \"Phencyclidine (PCP) intoxication in children and adolescents\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Salvia divinorum is a perennial herb of the mint family that is gaining popularity among adolescents and young adults because of its easy availability. Plants, leaves, and extracts are available for purchase over the internet, where it is marketed as a legal and safe hallucinogen on many websites. Unlike many of the other hallucinations, Salvinorin A, the psychoactive component of Salvia divinorum, displays no serotonergic activity. Instead, Salvinorin A is a potent kappa-opioid receptor agonist, provoking dysphoria, synesthesia, and visual hallucinations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44584?source=see_link&amp;anchor=H18#H18\">",
"       \"Intoxication from LSD and other common hallucinogens\", section on 'Salvia divinorum'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Marijuana",
"      </strong>",
"      &ndash; Marijuana exposure has also been reported to cause psychotic symptoms either alone or when adulterated with PCP and smoked. There is also evidence that marijuana alone may precipitate schizophreniform symptoms in patients with preexisting risk factors for psychiatric disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21783?source=see_link&amp;anchor=H4#H4\">",
"       \"Cannabis use disorders: Clinical features and diagnosis\", section on 'Mood, perception, thought content'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Drug-related syndromes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Serotonin syndrome",
"      </strong>",
"      &ndash; Serotonin syndrome is a potentially life-threatening condition associated with increased serotonergic activity in the central nervous system (CNS) that may be mistaken for psychosis. Mental status changes can include anxiety, agitated delirium, restlessness, and disorientation. In addition, patients often exhibit autonomic manifestations (eg, diaphoresis, tachycardia, hyperthermia, hypertension) and neuromuscular hyperactivity (eg, hyperreflexia, clonus, lower extremity rigidity). It is seen with therapeutic medication use, inadvertent interactions between drugs, and intentional self-poisoning. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"       \"Serotonin syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7878?source=see_link\">",
"       Baclofen",
"      </a>",
"      <strong>",
"       withdrawal",
"      </strong>",
"      &ndash; Baclofen withdrawal may be seen in children with cerebral palsy or spinal cord injury who are receiving intrathecal baclofen to treat spasticity. Pump emptying or malfunction can precipitate signs of baclofen withdrawal, including hallucinations, hyperthermia, tachycardia, hypertension or hypotension, and rigidity [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/11\">",
"       11",
"      </a>",
"      ]. Baclofen withdrawal must be considered in any child with a history of chronic baclofen exposure who presents with symptoms of psychosis. The resulting muscle rigidity and hyperthermia may require emergent treatment with baclofen",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      endotracheal intubation with neuromuscular paralysis. Left untreated, the muscle rigidity accompanying baclofen withdrawal may lead to rhabdomyolysis, hyperthermia, severe lactic acidosis, hepatic injury, renal failure, and death.",
"     </li>",
"     <li>",
"      <strong>",
"       Benzodiazepine (sedative) withdrawal",
"      </strong>",
"      &ndash; Withdrawal syndromes are an important and potentially life-threatening cause of psychosis in children receiving benzodiazepines and other sedatives chronically during pediatric intensive care [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/12\">",
"       12",
"      </a>",
"      ]. Central nervous system stimulation with hallucinations and seizures may occur if unrecognized. Tapering of intravenous dose and, when possible, switching to oral administration are therapeutic options to prevent withdrawal in these patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=see_link\">",
"       \"Benzodiazepine poisoning and withdrawal\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Neuroleptic malignant syndrome (NMS)",
"      </strong>",
"      &ndash; NMS is a rare syndrome in children receiving typical and atypical neuroleptic agents. It is characterized by fever, rigidity, and altered mental status (eg, agitated delirium, confusion, mutism, or catatonia). While symptoms usually develop during the first two weeks of neuroleptic therapy, the association of NMS with drug use is idiosyncratic. NMS can occur after a single dose. Complications include rhabdomyolysis, renal failure, and death. Treatment of this condition requires rapid recognition, aggressive cooling measures, including intubation and paralysis for extreme hyperthermia, and dopaminergic agents, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/42/4775?source=see_link\">",
"       bromocriptine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/62/17383?source=see_link\">",
"       amantadine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"       \"Neuroleptic malignant syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Drug-induced psychosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Steroid-induced psychosis",
"      </strong>",
"      &ndash; Steroid-induced psychosis is a well-known complication of glucocorticoid therapy in adults, and has been reported in children [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. In many cases, withdrawal of the steroid is sufficient to reverse psychosis, but some patients may require a brief course of antipsychotic medication, particularly when the steroid cannot be stopped [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/14\">",
"       14",
"      </a>",
"      ]. Response to antipsychotic drug treatment is typically complete and occurs within two weeks of initiation of neuroleptics. Patients with systemic lupus erythematosus (SLE) who are on higher doses of corticosteroids present a particular problem, since it is often difficult to differentiate psychosis due to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      from neuropsychiatric lupus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link&amp;anchor=H21#H21\">",
"       \"Major side effects of systemic glucocorticoids\", section on 'Central nervous system'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38631?source=see_link\">",
"       \"Neuropsychiatric manifestations of systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=see_link\">",
"       Isoniazid",
"      </a>",
"      <strong>",
"       -induced psychosis",
"      </strong>",
"      &ndash; Isoniazid (INH)-induced psychosis is a rare complication of antituberculous therapy that has been reported widely in patients who have no prior psychiatric history [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/15\">",
"       15",
"      </a>",
"      ]. Symptoms of psychosis typically begin days to weeks after initiation of INH therapy. The mechanism of INH induced psychosis has been not been completely elucidated; however, pyridoxine has not been shown to prevent or treat the psychosis symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Antibiotic-induced mania",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      have rarely caused neuropsychiatric symptoms including anxiety and hallucinations. The exact mechanism by which these antibiotics may cause psychosis is unknown [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Anticonvulsants",
"      </strong>",
"      &ndash; Anticonvulsants, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"       topiramate",
"      </a>",
"      , have also been associated with psychosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Central nervous system (CNS) abnormality",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       CNS mass lesion",
"      </strong>",
"      &ndash; Psychosis can represent an unusual presentation of mass lesion in the CNS (eg, brain tumor, brain abscess); more typical symptoms include headaches, nausea, seizure, personality change and aphasia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/56/13192?source=see_link\">",
"       \"Clinical manifestations and diagnosis of central nervous system tumors in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Intracranial injury",
"      </strong>",
"      &ndash; Any traumatic insult to the brain, including both extra- and intra-axial bleeding, can rarely cause altered mental status with delirium and visual or auditory hallucinations [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/19\">",
"       19",
"      </a>",
"      ]. However, progressive depression of consciousness is much more common. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29464?source=see_link\">",
"       \"Intracranial subdural hematoma in children: Clinical features, evaluation, and management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link\">",
"       \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"       \"Initial approach to severe traumatic brain injury in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Stroke",
"      </strong>",
"      &ndash; Stroke may lead to behavior changes with hallucinations depending on the region of the brain that is rendered ischemic. However, neurologic deficits (eg, aphasia, hemiplegia, visual changes) are almost always present as well. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=see_link\">",
"       \"Ischemic stroke in children and young adults: Etiology and clinical features\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       CNS infections",
"      </strong>",
"      &ndash; In children, any serious CNS infection (eg, meningitis, encephalitis) may cause visual hallucinations with altered mental status. Specific association with psychosis has been described for Chlamydophila (Chlamydia) pneumoniae, Mycoplasma pneumoniae, Epstein-Barr virus (\"Alice-in-Wonderland\" syndrome), and cerebral malaria [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. A history or suspicion of HIV infection should prompt consideration of less common disease processes including toxoplasmosis and progressive multifocal leukoencephalopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"       \"Approach to HIV-infected patients with central nervous system lesions\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations of malaria\", section on 'Cerebral malaria'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Neurologic findings'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Postictal psychosis",
"      </strong>",
"      &ndash; Postictal psychosis is a rare complication of epilepsy that may start hours to days after a prolonged seizure. The resulting hallucinations may last more than one week [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Temporal lobe epilepsy",
"      </strong>",
"      &ndash; Auditory and visual hallucinations may arise from temporal lobe epilepsy in children [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/25\">",
"       25",
"      </a>",
"      ]. This disorder may present with acute, brief episodes of psychosis despite treatment with anticonvulsant medications. Unlike childhood onset schizophrenia, these patients may have insight into hallucinations and rapidly respond to antipsychotics [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link&amp;anchor=H7#H7\">",
"       \"Localization-related (partial) epilepsy: Causes and clinical features\", section on 'Clinical and EEG features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Landau-Kleffner syndrome",
"      </strong>",
"      &ndash; The Landau-Kleffner syndrome (also called acquired epileptic aphasia) is an extremely rare syndrome in which deterioration of higher cortical functioning, in this case, language capability, is lost because of frequent epileptiform activity. Mutism and behavioral outbursts may be seen. The presentation may mimic that of childhood psychosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link\">",
"       \"Epilepsy syndromes in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Subacute sclerosing panencephalitis",
"      </strong>",
"      &ndash; Subacute sclerosing panencephalitis (SSPE) is a progressive, fatal disease of the central nervous system. The measles virus has been implicated in the pathogenesis of SSPE. However, symptoms may develop years after the initial measles infection. SSPE is a rare cause of psychosis, but should be considered in any patient who has had a primary measles infection [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical presentation and diagnosis of measles\", section on 'Subacute sclerosing panencephalitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus (SLE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosis is frequently seen in children and adolescents with SLE and central nervous system inflammation. Patients with SLE may describe auditory or tactile hallucinations. The use of steroids in many patients with SLE further complicates the diagnosis; however, SLE-induced psychosis is typically accompanied by headache, confusion, and difficulty with concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link\">",
"     \"Systemic lupus erythematosus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Metabolic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a rare cause of psychosis, metabolic disease is an important consideration when evaluating acute psychosis, especially in adolescents. Diagnosis during the stage of early psychiatric manifestations may allow for treatment and prevention of permanent neurologic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Urea cycle defects",
"      </strong>",
"      &ndash; Patients who have partial urea cycle enzyme deficiencies may have atypical presentations consisting of recurrent episodes of bizarre behavior, hallucinations, or delusions during adolescence and adulthood. These patients also typically complain of headache and vomiting. This delayed presentation is most common with partial ornithine transcarbamylase deficiency, although it also occurs with partial activity of all urea cycle enzymes. These patients tend to prefer vegetarian diets because dietary protein intake often is associated with headache. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=see_link\">",
"       \"Urea cycle disorders: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Acute intermittent porphyria (AIP)",
"      </strong>",
"      &ndash; AIP is both the most common and most severe of the rare inherited porphyrias. It is an autosomal dominant disorder resulting from a partial deficiency of porphobilinogen deaminase (PBGD) activity, the third enzyme in the pathway of heme synthesis. Psychiatric complaints may be prominent in AIP, and may represent the sole feature of the disease. These include hysteria, anxiety, apathy, depression, phobias, psychosis, organic disorders, agitation, delirium, and altered consciousness, ranging from somnolence to coma. Some patients with AIP develop a psychosis similar to schizophrenia. Previously asymptomatic patients may develop acute psychosis after precipitating factors such as drugs that induce the P450 microsomal oxidase system (eg, barbiturates), fasting, intercurrent illness, and premenstrual hormonal changes in women. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=see_link\">",
"       \"Etiology and pathogenesis of acute intermittent porphyria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Wilson's disease",
"      </strong>",
"      &ndash; An inherited disorder of copper metabolism, Wilson's disease may present during adolescence with subacute psychiatric symptoms ranging from depression to frank psychosis characterized by catatonia and paranoia. Wilson's disease is diagnosed by the findings of low ceruloplasmin concentrations and elevated urinary copper excretion. It is a potentially reversible cause of psychosis, and must be considered in any child or adolescent with new-onset psychiatric symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H69500449#H69500449\">",
"       \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Behavioral and psychiatric symptoms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other defects",
"      </strong>",
"      &ndash; Acute or subacute psychosis has also been reported as a prominent presenting feature in patients with homocysteine remethylation defects, homocystinuria, adrenoleukodystrophy, some lysosomal disorders, cerebrotendinous xanthomatosis, and alpha or beta mannosidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Postpartum psychosis",
"      </strong>",
"      &ndash; Postpartum psychosis is an uncommon condition seen up to 30 days after childbirth. It presents with paranoia, delusions, and hallucinations. Psychosis and lack of insight can lead to real risks to both the neonate and mother. Postpartum psychosis requires hospitalization for initiation of antipsychotics and stabilization [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Electrolyte disturbance",
"      </strong>",
"      &ndash; Children with hyponatremia or hypernatremia, often exhibit behavior changes and encephalopathy that may be difficult to distinguish from acute psychosis. Hypocalcemia and hypomagnesemia may rarely cause frank psychosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link\">",
"       \"Manifestations of hyponatremia and hypernatremia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=see_link\">",
"       \"Clinical manifestations of hypocalcemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=see_link&amp;anchor=H18#H18\">",
"       \"Acute toxic-metabolic encephalopathy in children\", section on 'Fluid and electrolyte disturbances'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Uremia or hepatic encephalopathy",
"      </strong>",
"      &ndash; Acute mental status changes with hallucinations commonly accompany uremia and hepatic encephalopathy in children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=see_link&amp;anchor=H22#H22\">",
"       \"Acute toxic-metabolic encephalopathy in children\", section on 'Organ failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hashimoto's encephalopathy (HE)",
"      </strong>",
"      &ndash; HE is a syndrome that is rarely seen in children and is associated with Hashimoto's thyroiditis. HE is believed to be an immune-mediated disorder rather than representing the direct effect of an altered thyroid state on the central nervous system. Psychosis, particularly visual hallucinations, but also paranoid delusions, have been reported in up to one third of patients and is responsive to corticosteroid therapy and treatment of a dysthyroid state, if present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33527?source=see_link\">",
"       \"Hashimoto's encephalopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Thyroid storm",
"      </strong>",
"      &ndash; Although most commonly seen in adults, children very rarely manifest symptoms of thyroid storm including tachycardia, heart failure, and hyperpyrexia (temperature elevation up to 106&ordm;F). Agitation, delirium, psychosis, stupor, or coma is usually associated with the diagnosis. Although thyroid storm can develop in patients with long-standing untreated hyperthyroidism, it is more often precipitated by an acute event such as thyroid or nonthyroidal surgery, trauma, infection, or an acute iodine load. Rarely, thyroid storm may be associated with ingestion of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/47/31480?source=see_link\">",
"       levothyroxine",
"      </a>",
"      (T4) in children [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33655?source=see_link\">",
"       \"Thyroid storm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Antiphospholipid syndrome",
"      </strong>",
"      &ndash; Antiphospholipid antibody syndrome is traditionally associated with hypercoagulability, thrombocytopenia, and increased risk of fetal loss. This syndrome has also been described in a nine year old child with psychosis without evidence of thrombotic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Psychiatric disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of primary psychiatric disease entities, including depression, bipolar disorder, childhood onset schizophrenia, and brief reactive psychosis may lead to psychotic symptoms. A history of mental illness in the family, emotional trauma, subacute to chronic symptoms, and coexistent mood disorder suggests a primary psychiatric disorder. However, a psychiatric diagnosis as a cause of psychosis in a child should be pursued only when the potentially fatal and potentially reversible causes of psychosis have been excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians must focus on obtaining an inclusive history in order to differentiate the broad range of conditions that may present with psychosis (",
"    <a class=\"graphic graphic_table graphicRef52785 \" href=\"UTD.htm?24/61/25564\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50275 \" href=\"UTD.htm?25/40/26251\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Differential diagnosis'",
"    </a>",
"    above.) Historical information of particular importance includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Setting suggestive of drug overdose (eg, adolescent brought from a rock concert, abrupt change in toddler behavior, and suspected ingestion).",
"     </li>",
"     <li>",
"      Drug toxicity suggested by patient's current medications (eg, corticosteroids, neuroleptic agents,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=see_link\">",
"       isoniazid",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The presence and severity of constitutional symptoms (fevers, chills, headache) indicating an infectious etiology (eg, meningitis, encephalitis).",
"     </li>",
"     <li>",
"      Known history of systemic lupus erythematosus (SLE) or findings (eg, arthralgias, myalgias, and rashes) suggestive of SLE.",
"     </li>",
"     <li>",
"      A history of head trauma (intracranial injury).",
"     </li>",
"     <li>",
"      New onset of neurologic deficits (stroke, brain abscess, brain tumor).",
"     </li>",
"     <li>",
"      Seizure disorder or signs suggestive of seizure disorder (Inattentiveness, rhythmic blinking or other stereotyped movements).",
"     </li>",
"     <li>",
"      Prior episodes associated with possible precipitating factors (eg, menstruation, medications, stress) vomiting, or headache suggestive of metabolic disease (urea cycle defects, acute intermittent porphyria).",
"     </li>",
"     <li>",
"      A family history of psychiatric disease or longstanding bizarre behaviors supporting a diagnosis of a psychiatric disease (although development of a psychotic disorder before the age of 12 is uncommon [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/31\">",
"       31",
"      </a>",
"      ]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings of hypoglycemia (altered mental status, diaphoresis, tachycardia or hypotension) and impaired oxygenation (cyanosis, pallor, shock, respiratory distress) require early identification and treatment in the child with acute psychosis. Once the potential for substrate deficiency is addressed, physical examination should focus on other findings suggestive of a specific etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mental status examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with psychiatric illness typically has normal vital signs, normal mental status (oriented to person, place, and time), and has intact memory with good cognitive functioning. Hallucinations are usually auditory in nature.",
"   </p>",
"   <p>",
"    In contrast, patients with psychosis caused by other medical illness usually have abnormal vital signs, altered mental status, and impaired orientation with compromised intellectual function. Visual and tactile hallucinations are frequently prominent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Suspected drug toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with possible pharmaceutical or drug toxicity presenting with psychotic features, constellations of physical findings can be interpreted in the context of toxic syndromes, or \"toxidromes\" (eg, serotonin syndrome, hallucinogen exposure, or anticholinergic or sympathomimetic agent overdose) (",
"    <a class=\"graphic graphic_table graphicRef71268 \" href=\"UTD.htm?43/6/44140\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to the child with occult toxic exposure\", section on 'Diagnosis of poisoning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention to vital signs, mental status, eye findings, and neurologic examination provide the greatest help in narrowing the differential diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Fever",
"      </strong>",
"      &ndash; Fever may occur with any infection, but may also signal intoxication with anticholinergic or sympathomimetic agents or withdrawal syndromes.",
"     </li>",
"     <li>",
"      <strong>",
"       Tachycardia",
"      </strong>",
"      &ndash; While mild tachycardia may be seen in the presence of primary psychiatric disease, marked tachycardia should prompt the search for infection,",
"      <span class=\"nowrap\">",
"       pharmacologic/drug",
"      </span>",
"      exposure, and withdrawal syndromes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Drug-related syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Eye findings",
"      </strong>",
"      &ndash; The presence of dilated pupils suggests anticholinergic or sympathomimetic symptoms. Nystagmus may indicate exposure to dissociative agents, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/21/34132?source=see_link\">",
"       dextromethorphan",
"      </a>",
"      , or phencyclidine. Ocular clonus can be seen in the setting of monoamine oxidase toxicity or serotonin syndrome. Conjunctival injection may suggest marijuana use. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link&amp;anchor=H10#H10\">",
"       \"Approach to the child with occult toxic exposure\", section on 'Diagnosis of poisoning'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Kayser-Fleischer rings are brownish or gray-green rings that represent fine pigmented granular deposits of copper in Descemet's membrane located in the cornea near the endothelial surface (",
"      <a class=\"graphic graphic_picture graphicRef65925 \" href=\"UTD.htm?19/26/19887\">",
"       picture 1",
"      </a>",
"      ). They are seen in 90 percent of patients with neurologic presentation of Wilson's disease but may require slit lamp examination for detection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link&amp;anchor=H59391898#H59391898\">",
"       \"Tests used in the diagnosis of Wilson disease\", section on 'Ocular slit-lamp examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Mouth and mucous membranes",
"      </strong>",
"      &ndash; Dry mucous membranes are a non-specific finding that can indicate anticholinergic toxicity, while sialorrhea may occur in the setting of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      use. Bruxism has been reported with a variety of serotonergic agents, especially ecstasy (MDMA).",
"     </li>",
"     <li>",
"      <strong>",
"       Neck",
"      </strong>",
"      &ndash; Thyromegaly should prompt serologic evaluation of thyroid function, and exclusion of thyrotoxicosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Abdominal and genitourinary exam",
"      </strong>",
"      &ndash; The presence or absence of bowel sounds can be supportive in distinguishing anticholinergic toxicity from sympathomimetic symptoms. Classically, anticholinergic toxicity slows peristalsis, resulting in decreased or absent bowel sounds. Urinary retention may also occur in the setting of anticholinergic exposure.",
"     </li>",
"     <li>",
"      <strong>",
"       Skin",
"      </strong>",
"      &ndash; Diaphoresis is a non-specific sign that occurs in the setting of hypoglycemia, hyperthyroidism, sympathomimetic exposure, or fever. Absence of sweating is a characteristic finding in anticholinergic toxicity. A malar rash suggests systemic lupus erythematosus, while track marks must prompt further questioning and testing regarding illicit drug use.",
"     </li>",
"     <li>",
"      <strong>",
"       Central nervous system (CNS)",
"      </strong>",
"      &ndash; The neurological examination is nonfocal in psychosis due to psychiatric illness. The presence of a focal or lateralizing examination suggests a CNS mass lesion, CNS hemorrhage, severe traumatic brain injury, or stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ANCILLARY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid blood glucose is of particular importance in the early assessment of children with acute psychosis, especially those with altered mental status. In addition, pulse oximetry or direct measurement of PaO2 by arterial blood gas should be obtained in those patients whose evaluation suggests cerebral hypoxia (respiratory distress, hemodynamic instability, pallor, or cyanosis). Patients with hypoglycemia or cerebral hypoxia require additional studies to determine the underlying cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to hypoglycemia in infants and children\", section on 'Diagnostic evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=see_link&amp;anchor=H30#H30\">",
"     \"Emergent evaluation of acute respiratory compromise in children\", section on 'Ancillary studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with normal blood glucose and oxygenation, the clinical presentation of psychosis largely dictates the extent of ancillary testing that is needed. For example, the adolescent with normal mental status, auditory hallucinations, and strong family history of schizophrenia requires limited, if any additional laboratory or diagnostic studies beyond a toxicology screen and, in females, a pregnancy test. However, a school age child with fever, visual hallucinations, and altered mental status warrants extensive evaluation that will likely include blood studies, brain imaging, and lumbar puncture. The following sections summarize laboratory and diagnostic studies that may assist in establishing the underlying diagnosis in children with acute psychosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Complete blood count (CBC)",
"      </strong>",
"      &ndash; An elevated white blood cell count may indicate infection, particularly meningitis or encephalitis, or stress reaction in children with fever. Severe anemia of any etiology may contribute to cerebral hypoxia, and thrombocytopenia raises the risk of a cerebral hemorrhage. Both thrombocytopenia and thrombocytosis may be signs of an acute phase reaction.",
"      <br/>",
"      <br/>",
"      Patients with systemic lupus erythematosus (SLE) may have evidence for a hemolytic anemia with accompanying leukopenia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia. Elevated erythrocyte sedimentation rate and antinuclear antibodies (ANA) may also be present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=see_link&amp;anchor=H10#H10\">",
"       \"Systemic lupus erythematosus in children\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Computed tomography (CT) scan of head",
"      </strong>",
"      &ndash; Children with findings of head trauma, focal neurologic deficits, or a decreased level of consciousness should undergo computed tomography of the brain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      magnetic resonance imaging. CT may also play a role in selected children with fever or visual hallucinations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"       \"Initial approach to severe traumatic brain injury in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lumbar puncture (LP)",
"      </strong>",
"      &ndash; A LP should be performed in children with signs of meningitis as long as findings of focal neurologic deficits are not present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=see_link\">",
"       \"Lumbar puncture: Indications, contraindications, technique, and complications in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Rapid drug screening of urine",
"      </strong>",
"      &ndash; A urine drug screen positive for cocaine, amphetamines, or phencyclidine (PCP) provides supporting evidence for drug abuse as a cause of psychosis. However, urine screens do not detect other toxic causes of psychosis (eg, lysergic acid diethylamide (LSD), ecstasy (MDMA),",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/21/34132?source=see_link\">",
"       dextromethorphan",
"      </a>",
"      ). In addition, positive and negative immunoassay screens for drugs do not absolutely confirm or refute poisoning diagnoses and may need confirmation by gas chromatography-mass spectrophotometry (GC-MS). The spectrum of drugs included in the urine screen varies by institution. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link&amp;anchor=H18#H18\">",
"       \"Approach to the child with occult toxic exposure\", section on 'Toxicology screens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Blood chemistries",
"      </strong>",
"      &ndash; Evaluation of serum chemistries can identify hypocalcemia, hypomagnesemia, hypernatremia, hyponatremia, and metabolic acidosis (seen in sepsis, severe sympathomimetic toxicity,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7878?source=see_link\">",
"       baclofen",
"      </a>",
"      withdrawal and some inborn errors of metabolism).",
"      <br/>",
"      <br/>",
"      Serum electrolytes, calcium, phosphate, magnesium, blood urea nitrogen, creatinine, thyroid function (T3, T4, thyroid stimulating hormone [TSH]), liver enzymes (eg, aspartate transferase [AST], alanine transferase [ALT]) and liver function tests (total and direct bilirubin, total protein, albumen, prothrombin time [PT]) are suggested in children and adolescents whose psychosis is not clearly psychiatric in origin and cannot be explained on the basis of substrate deficiency, drug toxicity, or central nervous system abnormality. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Other conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Electrocardiogram (EKG)",
"      </strong>",
"      &ndash; In patients with psychosis of unknown etiology, particularly those with anticholinergic features, an EKG should be obtained. The presence of an R wave in aVR suggests the presence of a tricyclic antidepressant, or similar substance (such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ). This EKG finding is seen in both therapeutic and toxic exposures. Toxicity is determined by the duration of the QRS interval. A prolonged QRS indicates blockade of conduction through fast sodium channels in the myocardium and is associated with ventricular dysrhythmias. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=see_link\">",
"       \"Tricyclic antidepressant poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Rapid urine pregnancy test",
"      </strong>",
"      &ndash; All postmenarchal girls should have urine pregnancy testing performed to help guide further therapeutic decisions with respect to safety of both mother and baby.",
"     </li>",
"     <li>",
"      <strong>",
"       Special metabolic studies",
"      </strong>",
"      &ndash; When metabolic disease is suspected, specialized studies of urine and blood are needed to confirm the diagnosis. Consultation with an expert in metabolic disease is of great value to ensure the proper test is performed and to identify the laboratory that is best prepared to perform the test. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H366024#H366024\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Initial evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13177?source=see_link&amp;anchor=H12033830#H12033830\">",
"       \"Inborn errors of metabolism: Identifying the specific disorder\", section on 'Laboratory evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations and diagnosis of acute intermittent porphyria\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link\">",
"       \"Tests used in the diagnosis of Wilson disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Electroencephalogram (EEG)",
"      </strong>",
"      &ndash; EEG is required in all patients with repeated seizures or suspected non-convulsive status epilepticus (eg, temporal lobe epilepsy) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child with new-onset psychosis must undergo rapid evaluation that focuses on identifying and treating substrate deficiency, drug toxicity, and central nervous system abnormalities (",
"    <a class=\"graphic graphic_algorithm graphicRef56663 \" href=\"UTD.htm?27/2/27680\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Physical restraint and sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;While identification and correction of the underlying etiology is vital to overall patient outcome, early management of agitation or violent behavior can be a critical part of diagnosis and treatment, preventing injury to both the patient and staff.",
"   </p>",
"   <p>",
"    The emergency provider should first try verbal deescalation of the agitated child or adolescent. Key components involve clear, calm statements of what will happen in the emergency department, reduction of environmental stimulation such as loud noise or bright lights, reassurance that the child's safety is of utmost concern, and involvement of ancillary personnel (eg, social work, psychiatry, security) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/34\">",
"     34",
"    </a>",
"    ]. If the patient cannot be verbally redirected, supine physical restraints should be employed and life-threatening hypoglycemia or hypoxia should be excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link&amp;anchor=H12#H12\">",
"     \"Assessment and management of the acutely agitated or violent adult\", section on 'Verbal techniques'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link&amp;anchor=H13#H13\">",
"     \"Assessment and management of the acutely agitated or violent adult\", section on 'Physical restraints'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no controlled trials that compare medications for the acute chemical restraint of children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/34\">",
"     34",
"    </a>",
"    ]. Practice patterns among pediatric emergency physicians suggest that benzodiazepines are favored, although typical antipsychotics are also used [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If agitation persists with physical restraint, then judicious sedation with an intravenous or intramuscular benzodiazepine (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.05 to 0.1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    is an option in children with undifferentiated agitation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]. These agents have the advantages of quick onset, short elimination half-life and utility in patient withdrawal from alcohol or benzodiazepines. Adverse effects include sedation, central nervous system depression, and paradoxical reactions that result in excitation of the patient. Paradoxical reactions may be more common in children with developmental delay. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link&amp;anchor=H19#H19\">",
"     \"Assessment and management of the acutely agitated or violent adult\", section on 'Benzodiazepines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typical antipsychotic agent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/51/38711?source=see_link\">",
"     haloperidol",
"    </a>",
"    (dose 0.025 to 0.075",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose, maximum: 5 mg) is an alternative to benzodiazepine sedation in the acutely psychotic child or adolescent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/35/4666/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. The onset of antipsychotic activity for most neuroleptic agents is delayed on the order of days. However, the sedating properties of neuroleptics often aid in the management of the agitated patient. Many of the severe adverse effects associated with neuroleptics tend to occur in chronic dosing, including pancreatitis, diabetic ketoacidosis, extrapyramidal symptoms, and agranulocytosis. However, serious side effects may occur acutely, including dystonia, hypotension, and electrocardiographic interval prolongation. Children may be at greater risk of developing dystonia than adults. The clinician should also be vigilant for manifestations of neuroleptic malignant syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link&amp;anchor=H20#H20\">",
"     \"Assessment and management of the acutely agitated or violent adult\", section on 'First generation (typical) antipsychotics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Substrate deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid recognition of hypoglycemia and cerebral hypoxia is essential; all patients with a change in mental status require bedside glucose testing, or empiric therapy with dextrose containing solutions, if evaluation of serum glucose is delayed. Empiric treatment with supplemental oxygen is warranted until oxygenation can be assessed by pulse oximetry or arterial blood gas measurement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Vital sign abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild tachycardia may occur in the setting of primary psychiatric disease, however, marked vital sign abnormalities indicate another medical etiology for psychosis. Fever and tachycardia mandate the search for an infectious process, such as meningoencephalitis. Hyperthermia, tachycardia, or hypertension may also occur in the setting of sympathomimetic and anticholinergic toxicity, thyroid storm, or withdrawal syndromes, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7878?source=see_link\">",
"     baclofen",
"    </a>",
"    withdrawal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Neurologic deficit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal neurologic findings warrant emergent brain imaging that may show a brain tumor, brain, abscess, stroke, or cerebral hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Mental status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have altered mental status without evidence for drug intoxication (eg, PCP,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/21/34132?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef50275 \" href=\"UTD.htm?25/40/26251\">",
"     table 2",
"    </a>",
"    ) warrant a diligent evaluation, including laboratory studies, brain imaging, and rarely electroencephalogram (EEG) to identify the underlying etiology. Children with normal mental status and auditory hallucinations should undergo urgent psychiatric evaluation. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Mental status examination'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Ancillary studies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The new onset of psychosis in a child or adolescent must prompt consideration of other medical etiologies prior to primary psychiatric diagnosis. The approach to acute psychosis in children and adolescents is summarized in the algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef56663 \" href=\"UTD.htm?27/2/27680\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Assessment for hypoglycemia, hypoxia, altered mental status, abnormal vital signs, and neurologic deficit should proceed once the patient can be safely evaluated.",
"     </li>",
"     <li>",
"      The tables summarize drug toxicities and nonpsychiatric medical diagnoses associated with acute psychosis in children, highlighting the most common and the most life threatening causes (",
"      <a class=\"graphic graphic_table graphicRef50275 \" href=\"UTD.htm?25/40/26251\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52785 \" href=\"UTD.htm?24/61/25564\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Given the extensive range of potential causes for psychosis, stepwise and meticulous attention to history, vital signs, physical examination, and ancillary testing should facilitate exclusion of potentially reversible causes of psychosis.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Davids K, Charney D, Coyle J Nemeroff C. Neuropsychopharmacology, Lippincott Williams &amp; Wilkins, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/2\">",
"      Brady WJ Jr, Duncan CW. Hypoglycemia masquerading as acute psychosis and acute cocaine intoxication. Am J Emerg Med 1999; 17:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/3\">",
"      Hussain K, Mundy H, Aynsley-Green A, Champion M. A child presenting with disordered consciousness, hallucinations, screaming episodes and abdominal pain. Eur J Pediatr 2002; 161:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/4\">",
"      Frampton A, Spinks J. Hyperthermia associated with central anticholinergic syndrome caused by a transdermal hyoscine patch in a child with cerebral palsy. Emerg Med J 2005; 22:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/5\">",
"      G&ouml;pel C, Laufer C, Marcus A. Three cases of angel's trumpet tea-induced psychosis in adolescent substance abusers. Nord J Psychiatry 2002; 56:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/6\">",
"      Soutullo CA, Cottingham EM, Keck PE Jr. Psychosis associated with pseudoephedrine and dextromethorphan. J Am Acad Child Adolesc Psychiatry 1999; 38:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/7\">",
"      Calello DP, Osterhoudt KC. Acute psychosis associated with therapeutic use of dextroamphetamine. Pediatrics 2004; 113:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/8\">",
"      Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry 2004; 185:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/9\">",
"      Shannon M. Methylenedioxymethamphetamine (MDMA, \"Ecstasy\"). Pediatr Emerg Care 2000; 16:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/10\">",
"      Farber NB. The NMDA receptor hypofunction model of psychosis. Ann N Y Acad Sci 2003; 1003:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/11\">",
"      Shirley KW, Kothare S, Piatt JH Jr, Adirim TA. Intrathecal baclofen overdose and withdrawal. Pediatr Emerg Care 2006; 22:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/12\">",
"      Tobias JD. Tolerance, withdrawal, and physical dependency after long-term sedation and analgesia of children in the pediatric intensive care unit. Crit Care Med 2000; 28:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/13\">",
"      Dawson KL, Carter ER. A steroid-induced acute psychosis in a child with asthma. Pediatr Pulmonol 1998; 26:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/14\">",
"      Ingram DG, Hagemann TM. Promethazine treatment of steroid-induced psychosis in a child. Ann Pharmacother 2003; 37:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/15\">",
"      Duke T, Mai M. Meningitis or madness: a delicate balance. J Paediatr Child Health 1999; 35:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/16\">",
"      Iannaccone R, Sue YJ, Avner JR. Suicidal psychosis secondary to isoniazid. Pediatr Emerg Care 2002; 18:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/17\">",
"      Przybylo HJ, Przybylo JH, Todd Davis A, Cot&eacute; CJ. Acute psychosis after anesthesia: the case for antibiomania. Paediatr Anaesth 2005; 15:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/18\">",
"      Kanner AM, Dunn DW. Diagnosis and management of depression and psychosis in children and adolescents with epilepsy. J Child Neurol 2004; 19 Suppl 1:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/19\">",
"      Richards CF, Gurr DE. Psychosis. Emerg Med Clin North Am 2000; 18:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/20\">",
"      Xavier M, Correa B, Coromina M, et al. Sudden psychotic episode probably due to meningoencephalitis and Chlamydia pneumoniae acute infection. Clin Pract Epidemiol Ment Health 2005; 1:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/21\">",
"      Nguyen TH, Day NP, Ly VC, et al. Post-malaria neurological syndrome. Lancet 1996; 348:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/22\">",
"      Thomas NH, Collins JE, Robb SA, Robinson RO. Mycoplasma pneumoniae infection and neurological disease. Arch Dis Child 1993; 69:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/23\">",
"      Nissenkorn A, Moldavsky M, Lorberboym M, et al. Postictal psychosis in a child. J Child Neurol 1999; 14:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/24\">",
"      Logsdail SJ, Toone BK. Post-ictal psychoses. A clinical and phenomenological description. Br J Psychiatry 1988; 152:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/25\">",
"      Oner O, Unal O, Deda G. A case of psychosis with temporal lobe epilepsy: SPECT changes with treatment. Pediatr Neurol 2005; 32:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/26\">",
"      Caplan R, Tanguay PE, Szekely AG. Subacute sclerosing panencephalitis presenting as childhood psychosis. J Am Acad Child Adolesc Psychiatry 1987; 26:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/27\">",
"      Sedel F, Baumann N, Turpin JC, et al. Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis 2007; 30:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/28\">",
"      Sit D, Rothschild AJ, Wisner KL. A review of postpartum psychosis. J Womens Health (Larchmt) 2006; 15:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/29\">",
"      Majlesi N, Greller HA, McGuigan MA, et al. Thyroid storm after pediatric levothyroxine ingestion. Pediatrics 2010; 126:e470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/30\">",
"      Shabana M, Shalaby M, Alhumayed S, Alshehri A. Paediatric case report: primary antiphospholipid syndrome presented with non-thrombotic neurological picture psychosis; treat by antidepressants alone? Int J Rheum Dis 2009; 12:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/31\">",
"      Reimherr JP, McClellan JM. Diagnostic challenges in children and adolescents with psychotic disorders. J Clin Psychiatry 2004; 65 Suppl 6:5.",
"     </a>",
"    </li>",
"    <li>",
"     Chun TH, Sargent J, Hodas GR. Psychiatric emergencies. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1820.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/33\">",
"      Fisch N, Goldberg-Stern H, Kivity S, et al. A 9-year old boy with acute psychosis and non-convulsive status epilepticus. Eur Psychiatry 2011; 26:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/34\">",
"      Hilt RJ, Woodward TA. Agitation treatment for pediatric emergency patients. J Am Acad Child Adolesc Psychiatry 2008; 47:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/35\">",
"      Dorfman DH, Kastner B. The use of restraint for pediatric psychiatric patients in emergency departments. Pediatr Emerg Care 2004; 20:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/35/4666/abstract/36\">",
"      Sorrentino A. Chemical restraints for the agitated, violent, or psychotic pediatric patient in the emergency department: controversies and recommendations. Curr Opin Pediatr 2004; 16:201.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6440 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AC55A795B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_35_4666=[""].join("\n");
var outline_f4_35_4666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Substrate deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Drug toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Drug overdose or abuse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Drug-related syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Drug-induced psychosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Central nervous system (CNS) abnormality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Systemic lupus erythematosus (SLE)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Metabolic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Psychiatric disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mental status examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Suspected drug toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ANCILLARY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Physical restraint and sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Substrate deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Vital sign abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Neurologic deficit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Mental status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6440\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6440|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?27/2/27680\" title=\"algorithm 1\">",
"      Approach psychosis child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6440|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/26/19887\" title=\"picture 1\">",
"      Kayser Fleischer ring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6440|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/61/25564\" title=\"table 1\">",
"      Organic psychosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/40/26251\" title=\"table 2\">",
"      Drug psychosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/6/44140\" title=\"table 3\">",
"      Poisoning syndromes - toxidromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=related_link\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=related_link\">",
"      Approach to HIV-infected patients with central nervous system lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=related_link\">",
"      Assessment and management of the acutely agitated or violent adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21783?source=related_link\">",
"      Cannabis use disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=related_link\">",
"      Clinical manifestations and diagnosis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/56/13192?source=related_link\">",
"      Clinical manifestations and diagnosis of central nervous system tumors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=related_link\">",
"      Clinical manifestations of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=related_link\">",
"      Clinical presentation and diagnosis of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17353?source=related_link\">",
"      Dextromethorphan poisoning: Epidemiology, pharmacology and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=related_link\">",
"      Emergent evaluation of acute respiratory compromise in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=related_link\">",
"      Etiology and pathogenesis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33527?source=related_link\">",
"      Hashimoto's encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13177?source=related_link\">",
"      Inborn errors of metabolism: Identifying the specific disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44584?source=related_link\">",
"      Intoxication from LSD and other common hallucinogens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=related_link\">",
"      Intracranial epidural hematoma in children: Clinical features, evaluation, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29464?source=related_link\">",
"      Intracranial subdural hematoma in children: Clinical features, evaluation, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=related_link\">",
"      Ischemic stroke in children and young adults: Etiology and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40935?source=related_link\">",
"      Ketamine poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=related_link\">",
"      Lumbar puncture: Indications, contraindications, technique, and complications in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=related_link\">",
"      MDMA (ecstasy) intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=related_link\">",
"      Methamphetamine intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38631?source=related_link\">",
"      Neuropsychiatric manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/570?source=related_link\">",
"      Phencyclidine (PCP) intoxication in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=related_link\">",
"      Tests used in the diagnosis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33655?source=related_link\">",
"      Thyroid storm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=related_link\">",
"      Urea cycle disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_35_4667="Drivers with mplantable defibrillators";
var content_f4_35_4667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for certification for commercial drivers with implantable defibrillators",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Physiologic/functional",
"      </td>",
"      <td class=\"subtitle1\">",
"       Certification",
"      </td>",
"      <td class=\"subtitle1\">",
"       Re-certification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Primary prevention",
"      </td>",
"      <td>",
"       Patient has high risk for death and sudden incapacitation",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Secondary prevention",
"      </td>",
"      <td>",
"       Patient demonstrated to have high risk for death and sudden incapacitation",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Blumenthal R, Braunstein J, Connolly H, et al. Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers, October 2002. Federal Motor Carrier Safety Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_35_4667=[""].join("\n");
var outline_f4_35_4667=null;
var title_f4_35_4668="T stage esophageal cancer";
var content_f4_35_4668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    T stage definitions for esophageal cancer (both squamous cell and adenocarcinoma)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       Primary tumor (T)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td>",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td>",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       High-grade dysplasia&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T1",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       Tumor invades lamina propria, muscularis mucosae, or submucosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1a",
"      </td>",
"      <td class=\"sublist_other\">",
"       Tumor invades lamina propria or muscularis mucosae",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1b",
"      </td>",
"      <td class=\"sublist_other\">",
"       Tumor invades submucosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       Tumor invades muscularis propria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       Tumor invades adventitia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T4",
"      </td>",
"      <td class=\"sublist_other_start\">",
"       Tumor invades adjacent structures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T4a",
"      </td>",
"      <td class=\"sublist_other\">",
"       Resectable tumor invading pleura, pericardium, or diaphragm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T4b",
"      </td>",
"      <td class=\"sublist_other\">",
"       Unresectable tumor invading other adjacent structures, such as aorta, vertebral body, trachea, etc.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * At least maximal dimension of the tumor must be recorded and multiple tumors require the T(m) suffix.",
"     <br>",
"      &bull; High-grade dysplasia includes all noninvasive neoplastic epithelia that was formerly called carcinoma in situ, a diagnosis that is no longer used for columnar mucosae anywhere in the gastrointestinal tract.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_35_4668=[""].join("\n");
var outline_f4_35_4668=null;
var title_f4_35_4669="HCW prophylaxis recs I";
var content_f4_35_4669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Postexposure prophylaxis for vaccine preventable diseases in healthcare workers - I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Definition of",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Prophylaxis",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Work restrictions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Susceptible",
"       </td>",
"       <td class=\"subtitle2\">",
"        Exposed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Hepatitis B",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Never or incompletely vaccinated and never had an anti-HBs titer &gt;10 IU/mL",
"       </td>",
"       <td>",
"        <p>",
"         Contact with contaminated blood or body fluid via percutaneous, membrane or non-intact skin exposure;",
"        </p>",
"        <p>",
"         <strong>",
"          Source",
"         </strong>",
"         - known HBsAg positive",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Never vaccinated",
"         </strong>",
"         - HBIG 0.06 mL/kg x1 and initiate vaccine series",
"        </p>",
"        <p>",
"         <strong>",
"          Nonresponder",
"         </strong>",
"         - HBIG x2 Response unknown - test healthcare worker; HBIG x1 if not protected and boost or complete vaccination",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        <p>",
"         <strong>",
"          Acute infection",
"         </strong>",
"         - relieve from direct patient contact until jaundice resolves;",
"        </p>",
"        <p>",
"         <strong>",
"          Chronic infection",
"         </strong>",
"         - counsel healthcare worker on infection control practices - if transmission occurs, restrict from invasive procedures and direct contact with patient equipment until hepatitis B antigenemia resolves",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Contact with contaminated blood or body fluid via percutaneous, membrane or non-intact skin exposure;",
"        </p>",
"        <p>",
"         <strong>",
"          Source",
"         </strong>",
"         - known HBsAg negative",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Never vaccinated",
"         </strong>",
"         - Initiate vaccine series",
"        </p>",
"        <p>",
"         <strong>",
"          Nonresponder or response unknown",
"         </strong>",
"         - no treatment needed",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Contact with contaminated blood or body fluid via percutaneous, membrane or non-intact skin exposure;",
"        </p>",
"        <p>",
"         <strong>",
"          Source",
"         </strong>",
"         - unknown HBsAg",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Never vaccinated",
"         </strong>",
"         - initiate vaccine series",
"        </p>",
"        <p>",
"         <strong>",
"          Nonresponder",
"         </strong>",
"         - treat as HBsAg positive if high risk source",
"        </p>",
"        <p>",
"         <strong>",
"          Response unknown",
"         </strong>",
"         - test healthcare worker; if not protected complete vaccination or begin revaccination.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Influenza",
"       </td>",
"       <td>",
"        Did not recieve annual immunization",
"       </td>",
"       <td>",
"        Cohabiting confined air space or face to face contact in open area",
"       </td>",
"       <td>",
"        Catch-up immunization and consider amantidine or rimantidine 100 mg PO BID or oseltamivir 75 mg PO QD or BID",
"       </td>",
"       <td>",
"        Relieve from care of high risk patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measles",
"       </td>",
"       <td>",
"        None of the following - documentation of diagnosis of measles by a physician, serologic evidence of immunity, two doses of MMR",
"       </td>",
"       <td>",
"        Cohabiting confined air space or face to face in open area",
"       </td>",
"       <td>",
"        Measles vaccine if no contraindications or immune globulin 0.25 mL/kg (maximum 15 mL) within 6 days or exposure",
"       </td>",
"       <td>",
"        Furlough from health-care facility until 4 days after rash appears or from day 5 after first exposure to day 21 after last exposure",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_35_4669=[""].join("\n");
var outline_f4_35_4669=null;
var title_f4_35_4670="Non Hodgkins lymphoma Endosc";
var content_f4_35_4670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Non-Hodgkin's lymphoma of the colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 222px; height: 221px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Colonoscopic view of a friable, indurated mucosa with scattered areas of ulceration suggestive of inflammatory bowel disease. Histology was consistent with a non-Hodgkin's lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_35_4670=[""].join("\n");
var outline_f4_35_4670=null;
var title_f4_35_4671="TEE aortic arch";
var content_f4_35_4671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/61705/tee_aortic_arch_conv.mp4?title=TEE+aortic+arch\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiogram (TEE) of the aortic arch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 317px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the large plaque and superimposed mobile thrombus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_35_4671=[""].join("\n");
var outline_f4_35_4671=null;
